# Template for Outsourcing

## Clause 1
{{party_name}} 10.20 (TRANSLATION) OUTSOURCING AGREEMENT This Outsourcing {{party_name}} (hereinafter “{{party_name}}”) is effective as from {{effective_date}}, by and between: Parties to this agreement SILICON SMELTERS « Pty » Ltd, registration nr 1998/019036/07, {{party_name}} n° {{effective_date}}, Registered office at Beyersnek Road, PO Box 657 {{party_name}} – South Africa, represented by {{party_name}}, Managing Director, acting pursuant to the powers granted to him by {{party_name}} (hereinafter referred to as “the {{party_name}}”), AND ESPACIO INFORMATION TECHNOLOGY, {{party_name}}., a public limited company with place of business in P° de la Castellana, N° 259, 28046, Madrid, SPAIN, and represented by Mr. {{party_name}} as Chief Executive, in virtue of his powers, currently in force, conferred to him {{effective_date}} (Protocol No. 134), before Mr. {{party_name}}, {{party_name}} in Madrid, (hereinafter referred to as “{{party_name}}”). 1 Source: {{party_name}}, {{party_name}}, {{effective_date}}. RECORDINGS This {{party_name}} is being made and entered into with reference to the following facts: 1.1. {{party_name}} and {{party_name}} both belong to the GROUP {{party_name}}. 1.2. The {{party_name}} is a company that manufactures ferro-alloys in both its factories: {{party_name}} and {{party_name}}. 1.3. {{party_name}} is a company that installs, integrates and develops the management and maintenance of {{party_name}}, and desires to perform for the {{party_name}} the outsourcing services described in this {{party_name}}. 1.4. GROUP {{party_name}} demands the {{party_name}} to use the management services of the group, developed and maintained by {{party_name}}, and subcontract the management of its IT infrastructure to {{party_name}}. In consideration of the payments to be made and services to be performed hereunder, the parties agree as follows: 2. {{party_name}} OF AGREEMENT 2.1. The {{party_name}} documents: 2.1.1. The services {{party_name}} renders to the {{party_name}}’s users on all the company’s levels; 2.1.2. The clauses made regarding services and products between the {{party_name}} and {{party_name}}. 2.1.3. The terms and conditions under which the {{party_name}} agrees to purchase and {{party_name}} agrees to provide the {{party_name}}. 2.2. The definitions that apply in the present {{party_name}} are listed in Annex 1. 2.3. The scope of application of this {{party_name}} is restricted to the IT Management System of the {{party_name}}. The IT involving the industrial and production environments is excluded from this {{party_name}}. 2.4. The supervision of the {{party_name}} is assured by {{party_name}}, represented by its Chief Executive, and by the {{party_name}}, represented by its {{party_name}}. 2.5. These specific services can be grouped in different types: 2.5.1. {{party_name}} 2 Source: {{party_name}}, {{party_name}}, {{effective_date}} 2.5.2. Servers 2.5.3. Applications 2.5.4. {{party_name}}. Standard software licences 2.5.6. Definition of the agreed guidelines for negotiation 3. {{party_name}} OF THE SERVICES RENDERED BY {{party_name}} The specific services rendered by {{party_name}} according to this {{party_name}} include the following: 3.1. NETWORK {{party_name}} is in charge of the remote {{party_name}}, which connects each workstation of the {{party_name}} to {{party_name}} of {{party_name}} and to Internet (hereinafter “{{party_name}}”). The internal network of the factories (hereinafter “{{party_name}}”) is excluded from this {{party_name}} and the {{party_name}} is responsible for it. 3.1.1. The {{party_name}} has contracted, taking into account the technological standards defined by {{party_name}}, an external company (hereinafter “{{party_name}} {{party_name}}”) for the setting up and the management of the {{party_name}}. This {{party_name}} {{party_name}} is accountable to the {{party_name}} for the management of the {{party_name}}. 3.1.2. {{party_name}} commits itself to monitor the {{party_name}} during working hours in South Africa, up to where the service rendered by the {{party_name}} {{party_name}} allows. 3.1.3. {{party_name}} commits itself to alert the IT Department of the {{party_name}} when any malfunction (power cut, saturation, etc.) is identified, and to carry out the necessary actions with the {{party_name}} {{party_name}} in order to solve this malfunction as quickly as possible. 3.1.4. {{party_name}} commits to assure a high availability (availability rate defined in Annex 2) and the proper performance (response time and no saturation) of the {{party_name}} during working hours in South Africa (established in Annex 2). 3.1.5. The {{party_name}} and {{party_name}} commit themselves to give each other notice of any case of malfunction with the {{party_name}} {{party_name}}. 3 Source: {{party_name}}, {{party_name}}, {{effective_date}}. SERVERS: 3.2.1. {{party_name}} is in charge of the list of servers (hereinafter “Servers”) provided in Annex 3. 3.2.2. The {{party_name}} is responsible for the maintenance of the hardware of the local servers. 3.2.3. {{party_name}} is responsible for the maintenance of the hardware of {{party_name}}. 3.2.4. {{party_name}} commits to monitor the Servers during working hours in South Africa. 3.2.5. {{party_name}} must alert the IT Department of the {{party_name}} if any problem should occur in any of the Servers, within the time established in Annex 2. 3.2.6. {{party_name}} commits to solve any problems that may arise in the Servers, within the time established in Annex 2. 3.2.7. {{party_name}} is in charge of supervising and assuring the proper performance of the backups. For this, it has provided the {{party_name}} with a backup process. 3.2.8. The {{party_name}} commits to follow the backup process that {{party_name}} has provided for him. 3.2.9. The {{party_name}} must alert {{party_name}} of any incidence it might detect by sending an electronic mail to sistemas@eit.es. 3.3. APPLICATIONS {{party_name}} provides and is responsible for the support and maintenance of the applications (defined in the table in {{party_name}}). For each of these applications, {{party_name}} commits to: 3.3.1. Provide the {{party_name}} with hardware installations (servers, disks, backup tapes, etc.) which enable the performance of the application. 3.3.2. Assure the availability of the application (which varies for each application, defined in Annex 2). 4 Source: {{party_name}}, {{party_name}}, {{effective_date}}. Monitor the applications to analyse the transaction charges and carry out the appropriate corrections in order to optimize the system. 3.3.4. Provide Level 2 assistance to users via direct telephone numbers of the persons responsible for each application, during the hours established in Annex 2. If there is a public holiday in Spain, {{party_name}} commits to provide for the {{party_name}} a central telephone number to communicate any incidences that may occur. 3.3.5. Solve the problems communicated by e-mail to incident.smelters@eit.es during working hours in South Africa, within time according to the severity of the problem, defined in Annex 2. 3.3.6. Maintain the present interfaces between the central application {{party_name}}-{{party_name}}US and the {{party_name}}’s local applications: {{party_name}} and Maximo. 3.3.7. Guarantee the reliability of the application (software and databases) and of the hardware support (server, disks, etc.), to prevent any loss of information that could affect the {{party_name}}’s business. 3.3.8. Carry out the backups and necessary restorations in order to assure the durability of the application and prevent any loss of information. 3.3.9. Guarantee a high service level (reasonable response time and correct progress of transactions). With regard to the electronic mail service, {{party_name}} will be able, after contacting with the {{party_name}}, to restrict the type and size of exchanged files. It is noted that the customer currently do not make use of this service but has the option to use it at no additional cost 3.3.10. Assure the security of the access to information: the {{party_name}} is responsible for the opening of accesses to the applications. {{party_name}} commits to supply the necessary securities to ensure the access rights defined by the {{party_name}} guarantee access only to the data authorized by the {{party_name}}. 3.4. WORKSTATIONS AND PRINTERS 3.4.1. The {{party_name}} is responsible for the purchase and maintenance of the workstations and printers. 3.4.2. {{party_name}} commits to assist the {{party_name}} to implement a master that allows the quick installation of all the standard software in workstations. 3.5. {{party_name}} LICENCES 3.5.1. The {{party_name}} will benefit from the group contracts negotiated by {{party_name}} in name of {{party_name}} for the purchase of licences. 3.5.2. The purchase of licences will be carried out directly by the {{party_name}}. 5 Source: {{party_name}}, {{party_name}}, {{effective_date}}. {{party_name}} declares and guarantees the {{party_name}} the legal purchase of licences of all the software necessary for the use of the central applications created by {{party_name}}. 3.5.4. {{party_name}} must inform the {{party_name}} in due course if any changes take place in licences or in their rights of use. 3.6. DEFINITION OF STA{{party_name}}RDS AND AGREED GUIDELINES {{party_name}} is responsible for: 3.6.1. The definition of the technological standards to be used in the {{party_name}}’s IT environment. 3.6.2. The agreed guidelines with the suppliers, in order to assure the provision of certain services or the purchase of certain IT tools which, according to {{party_name}}, are necessary for the provision of the mentioned services. 4. {{party_name}}. Apart from these services, {{party_name}} must provide other supplementary services, not considered in the present {{party_name}}. These services include the study, development and implementation of new applications, changing to new platforms, as well as any other service that the {{party_name}} may need in the field of IT services. 4.2. The terms and conditions of these services will be separately negotiated if and when it applies. 4.3. For that purpose and before the execution of the mentioned services by {{party_name}}, the {{party_name}} will pay {{party_name}} the package price, previously agreed by the parties. These services can either be carried out directly by {{party_name}} or by subcontracts in the sole discretion of {{party_name}}, which will have to notify the customer of this fact before the project commence. However if {{party_name}} decides to subcontract the project {{party_name}} remains responsible for the quality, the cost and the supervision of the services to the satisfaction of the customer. 6 Source: {{party_name}}, {{party_name}}, {{effective_date}}. WORK PLACE AND NATURE OF SERVICES 5.1. The services described in this {{party_name}} are provided from the following location: {{party_name}}, P° de la Castellana, {{effective_date}}, Madrid, SPAIN. 5.2. For this reason, {{party_name}} uses its own IT environment, as well as the local equipment of the {{party_name}}, connected by a teleprocessing system to {{party_name}} of {{party_name}}. 5.3. If necessary, {{party_name}} personnel will travel, in prior agreement with the {{party_name}}, to the different factories of the company. In this case, the travelling expenses (travel, accommodation and meals) will be paid by the {{party_name}}. 5.4. The IT environment belongs to {{party_name}} during the total course of the {{party_name}}, with exception of the services subcontracted to third parties by {{party_name}}, for which the subcontractor will be responsible. 5.5. {{party_name}} is responsible for the choice of the equipment considered the most appropriate in order to reach the service level convened in this {{party_name}}. This equipment, and its further updates, should it arise, will be shown to the {{party_name}} and agreed upon prior to purchase and installation and refusal by the customer will only be valid upon presentation of a justification to {{party_name}}. {{party_name}} is responsible for the maintenance of its own IT environment, as well as of its maintenance and modernization expenses. 5.5.1. {{party_name}} STAFF 5.5.1.1. The work team appointed by {{party_name}} to fullfill this {{party_name}} is responsible only to {{party_name}}, in accordance with the Spanish law. {{party_name}} will supervise and will be responsible for the behaviour and tasks of this team, especially on what concerns the confidentiality of the information. 5.5.1.2. The {{party_name}} does not have any responsibility for the accidents that might be suffered by the staff of {{party_name}}, or for the damages that might be caused by it to third parties, in the framework of its activities. 5.5.2. SUBCONTRACTING {{party_name}} assumes full responsibility for the execution of the tasks carried out by any subcontractor. The subcontractor is equally obliged to assure the service level, the confidentiality and the security convened in the {{party_name}}, for the provision of these services. It is the responsibility of {{party_name}} to enter into an agreement with the subcontractor to ensure their performance. 7 Source: {{party_name}}, {{party_name}}, {{effective_date}}. SUPERVISION OF THE SERVICE LEVEL 6.1. {{party_name}} commits to provide {{effective_date}} measurements to analyse the service level defined in Annex 2. 6.2. The parties will analyse {{effective_date}} these measurements in order to identify what can be improved. 6.3. The parties will review {{effective_date}} by mutual agreement the contents and aims of the Service Level {{party_name}}. 7. PAYMENTS AND PRICING 7.1. TOTAL {{effective_date}} AMOUNT The total {{effective_date}} amount to be paid, excluding taxes, for {{effective_date}}, for the total provision of the services described in Article 2 of this {{party_name}}, as well as the supervision of these (establishment of measurements and supervision meetings) will be: TWO HUNDRED THOU{{party_name}}ND EUROS ({{amount}}) 7.1.1. This amount has been fixed for the two factories of {{party_name}}: {{party_name}} and {{party_name}}, being the {{effective_date}} amount per factory A HUNDRED THOU{{party_name}}ND EUROS ({{amount}}). 7.1.2. If one of the factories closes down, the total amount due will be reduced pro rata for the rest of the {{effective_date}} period for the factory’s {{effective_date}} amount. 7.2. INVOICING 7.2.1. The invoicing of this amount will be carried out {{effective_date}}. The invoices will be issued by {{party_name}} at the start of each term. Such invoice must be paid by the customer within {{effective_date}} of the date on which the invoice is issued. 7.2.2. INFRASTRUCTURE COSTS 7.2.3. The costs of the communication lines, the network infrastructure, the local servers, the micro computing material (PC and printers) are the {{party_name}}’s responsibility and it is not included in the total {{effective_date}} amount defined in this {{party_name}}. 7.3. {{effective_date}} PAYMENT REVIEW 7.3.1. The amount defined in Article 6.1 will be subjected to {{effective_date}} revision, following the publication of the Consumer Price Index in Spain (Spanish CPI) in {{effective_date}} of each financial year by {{party_name}}. It will correspond to {{effective_date}} that has concluded. 8 Source: {{party_name}}, {{party_name}}, {{effective_date}}. The {{effective_date}} Package Price does not include a protection to inflation. For this reason, the amount will be adjusted {{effective_date}}, according to the growth of the Spanish CPI as was indicated above. 7.3.3. The new payment is calculated using the following formula: R = R0 * (S+1), where: 7.3.4. R0 is the payment corresponding to {{effective_date}}. 7.3.5. R is the new payment, and 7.3.6. S is the last Spanish CPI published on the revision date. 7.3.7. As a result, once {{effective_date}}, since the date the {{party_name}} was executed, has passed, and on this same date on {{effective_date}}, the {{effective_date}} price will be modified in proportion with the growth of the Spanish CPI. 7.3.8. In case that {{party_name}} does not publish the CPI or it be significantly modified in form and content, the parties will agree to a new equivalent measurement, which must be published at least {{effective_date}}. 8. INTELLECTUAL PROPERTY 8.1. {{party_name}} of the programmes in the application {{party_name}}-{{party_name}}US, used by the {{party_name}}’s exploitation of the management systems, belongs to {{party_name}}. 8.2. The rights of {{party_name}} also protect the programmes that might be created, and the data processing, accounts, and diagrams generated by the mentioned programme. 9. WARRANTY 9.1. {{party_name}} Adequacy 9.1.1. {{party_name}} guarantees that the solution suggested to the {{party_name}} in each moment is the best possible one for the needs of the {{party_name}}. 9.2. Cost Saving 9.2.1. {{party_name}} declares that the way of acting will always be governed by the cost saving principle. 9 Source: {{party_name}}, {{party_name}}, {{effective_date}} 9.3. Technology 9.3.1. {{party_name}} commits to maintain its IT environment in accordance to the technological advances, in order to prevent it from becoming obsolete. 9.4. {{party_name}}. {{party_name}} guarantees that the services described in this {{party_name}} will be rendered in accordance with the best practice, a quality level accepted by the {{party_name}}, and in accordance with the service levels defined in Annex 2. 9.5. Availability 9.5.1. The IT staff of {{party_name}} will carry out the exploitation of the services during working hours in South Africa, except for urgent actions that will be carried out exceptionally, if it were necessary, out of the established hours. 9.6. Data and {{party_name}} 9.6.1. {{party_name}} will produce a {{effective_date}} backup copy of the data and the applications residing in its IT environment, in order to re- establish and retrieve lost information. 10. {{party_name}} 10.1. {{party_name}} is responsible for any damages caused to the {{party_name}} or to third parties, when these result from {{party_name}} not satisfying the contractual obligations. 10.2. Nevertheless, {{party_name}} will be free of responsibility, in case of not satisfying its obligations, if he can prove that this was due to force majeure or external causes out of his control, like accidents, natural disasters, vandalism acts or theft. 10.3. The liability of {{party_name}} will be limited to a value equal to contractual value as per clause 7.1 and will not exceed this value. 10 Source: {{party_name}}, {{party_name}}, {{effective_date}}1. CONFIDENTIALITY The parties commit themselves to a total confidentiality and to not spread or use directly, through third parties or other companies, information about the other party to which they have access in the frame of this {{party_name}}. 11.1. PROTECTION AND {{party_name}} 11.1.1. {{party_name}} means any information disclosed by either party in the frame of this {{party_name}}. In consequence, each party agrees not to use, disclose, publish or disseminate any {{party_name}} of the other party for any purpose except to perform its obligations or exercise its rights under this {{party_name}}, except: 11.1.1.1. Following prior consent of the other party, or 11.1.1.2. If the information was in the public domain at the time it was disclosed or becomes in the public domain through no act or omission of {{party_name}}. 11.1.2. Any of these exceptions will not be presumed in any case, and the revealing party must clear any doubt to this respect. 11.1.3. Both parties shall take reasonable precautions to preserve in strict confidence any confidential or proprietary information obtained by them, their agents, employees, subcontractors, suppliers, consultants, and in general, any person that has access to it. 11.1.4. {{party_name}} includes any technical, economic, financial and/or commercial information, confidential or not, bearing in any commercial relationship and in general, without any limitation, any information to which any of the parties has access during the application, in the frame of this {{party_name}}. 11.1.5. Except as provided hereinafter, for a period of {{effective_date}} after termination or expiration of this {{party_name}}, each party shall not disclose, publish or disseminate information received from the other party which may be required to carry out this {{party_name}} and which the disclosing party deems proprietary and confidential. 11.1.6. Once this {{party_name}} has expired, each party must, depending on the choice of the other party, destroy or hand over all technical, economic, financial or commercial information, confidential or not, in its possession, directly or indirectly, as convened in the present {{party_name}}. 11 Source: {{party_name}}, {{party_name}}, {{effective_date}}1.2. MANAGEMENT OF ACCESS RIGHTS 11.2.1. In accordance to Article 10.1, the {{party_name}} is in charge of defining the opening, closing or modifying of access to information. The {{party_name}} is also in charge of defining the user accesses, as well as the level of access of its users. 11.2.2. 10.2.2. {{party_name}} guarantees the control of access (through an access code and password) to information pursuant to the access rights defined by the {{party_name}}. 11.2.3. 10.2.3. {{party_name}} will not be held responsible if a {{party_name}}’s user uses an access code and password of a third party. 12. SUPERVISION COMMISSION 12.1. The parties commit themselves to constitute a supervision commission formed by persons appointed for that purpose. 12.2. This commission will act as an intermediary between the parties and it will accomplish the following tasks: 12.2.1.1. Verify the fulfilment, in particular, the evolution and implementation, of all the services and applications. This operation will be recorded in the corresponding reports, according to the convened periodicity. 12.2.1.2. Interpret any Article of this {{party_name}} that might be questioned by the parties. 12.2.1.3. Resolve any potential conflict that may arise during the execution of this {{party_name}}. For this, the commission members will act at their best, and assemble all the necessary information. 12.3. If the commission members are not able to resolve a conflict or a problem in the interpretation of this {{party_name}} within {{effective_date}}, the representatives of the parties will be duly informed in order to find a solution on friendly terms. 12 Source: {{party_name}}, {{party_name}}, {{effective_date}}3. DURATION 13.1. The present {{party_name}} is effective as from 1 {{effective_date}} 2009. It is established by {{effective_date}} and renewed tacitly {{effective_date}}. 13.2. The {{party_name}} rests, for all that, cancellable at any time by any of the parties before the expiry date of the {{party_name}} or any of its renewals, upon {{effective_date}} prior written notice. 14. EARLY TERMINATION 14.1. The {{party_name}} can cancel, on its own accord, the present {{party_name}} upon certified notice to {{party_name}}, in the following cases: 14.1.1. If there is a repeated interruption, by {{party_name}}, of the services convened in this {{party_name}}, for a period of {{effective_date}}. 14.1.2. Upon the institution, by or against {{party_name}}, of insolvency, receivership or bankruptcy proceedings or any other proceedings for the settlement of its debts. 14.1.3. Non-performance by {{party_name}} of its contractual obligations and warranties, assumed in the present {{party_name}}. 14.1.4. Absorption or fusion of {{party_name}} by other companies. In this case, the {{party_name}} can decide if he wants to continue working with the new company, which will have to continue rendering all the services convened in this {{party_name}}, in the same conditions. 14.2. For simple convenience. 14.2.1. In case the {{party_name}} cancels the {{party_name}} in accordance with {{party_name}}, 13.2, {{party_name}} will pay the {{party_name}} the amount of {{amount}}, for the non observance of the {{party_name}} of which it is responsible. 14.2.2. In case of termination of this {{party_name}} by the {{party_name}} according to Article 13.5, the {{party_name}} will pay {{party_name}} the amount of {{amount}}. 15. {{party_name}} TRANSITION 15.1. In case of expiration or termination of the present {{party_name}}, the {{party_name}} and {{party_name}} will cooperate, in good faith, to make possible a transfer, in due form to the {{party_name}} or to a third party, chosen by the {{party_name}}, for the provision of the services defined in this {{party_name}}. For that purpose, the parties will develop, with enough time in advance and with the necessary haste, a Transition Plan where the actions and measures to be taken will be defined. 13 Source: {{party_name}}, {{party_name}}, {{effective_date}}5.2. {{party_name}} will continue to provide the services defined in this {{party_name}} between the date it receives from the {{party_name}} a notice of expiration or termination of this {{party_name}} and the date this expiration or termination becomes effective. 15.3. {{party_name}} commits to hand over to the {{party_name}}, on this date, all the data and its copies, in the frame of the provision of services. 16. {{party_name}} RULINGS 16.1. All the litigations that may arise between the parties during the period of application of the present {{party_name}}, in relation with its Articles, and that have not been solved in a friendly manner, will be subjected to the rulings of their respective Chief Executives. In case of persistent disagreement, the litigation will be subjected to the General Management of {{party_name}}. 16.2. However, if any of the parties no longer belongs to {{party_name}}, any litigation that may not be solved in a friendly manner will be settled in compliance with the laws of Spain. 16.3. Any doubt that arises, in the frame of this {{party_name}}, will be settled through arbitration in equity, in compliance with the Spanish Law of Arbitration, Ley 60/2003, both parties agreeing to obey the decision. For the designation of the arbitrators and the management of the arbitration, the following rules will apply: 16.3.1. There will be three arbitrators, solicitors. Each party will designate one, and these two will designate a third one. 16.3.2. The place of arbitration will be Madrid. {{effective_date}}. It will be governed by the laws of Spain and the language of the process will be Spanish. 16.3.4. The arbitrators will dictate the decision within {{effective_date}} of the notice of the parties’ acceptance. 16.4. The parties, expressly waiving the {{party_name}} that may correspond to the same, submit themselves to the jurisdiction of the Courts and Tribunals of Madrid for any matter derived from the present {{party_name}} that cannot be subjected to arbitration. 14 Source: {{party_name}}, {{party_name}}, {{effective_date}}7. GOVERNING LAW 17.1. This {{party_name}} shall be governed by, and construed in accordance with the laws of Spain. 18. IN WITNESS WHEREOF, the parties acknowledge that each has fully read and understood this {{party_name}}, and, intending to be legally bound thereby, executed this {{party_name}} on the date first above written. SLICON SMELTERS PTY LTD ESPACIO INFORMATION TECHNOLOGY, {{party_name}}: Dr B.E.N. {{party_name}} Name: {{party_name}} Pradal {{party_name}}: Managing Director {{party_name}}: Director General 15 Source: {{party_name}}, {{party_name}}, {{effective_date}} ANNEX 1: DEFINITIONS The following definitions apply in the present {{party_name}}: IT Department: {{party_name}}’s work team in charge of the support and maintenance of the {{party_name}}’s local infrastructure and applications. {{party_name}}: Internal network at the factories that connects the factory’s routers with the workstations and peripheral devices of the site. {{party_name}}: External network that connects the Silicon Smelter factories with the central node located in Madrid. {{party_name}} leaving the router of each factory. South African workdays: {{effective_date}}, except for legal holidays of the South African work schedule. South African working hours: 8h00 – 20h00 during South African workdays. {{party_name}}: Servers listed in Annex 3, which are located in the factories of {{party_name}}. Central Servers: Servers listed in Annex 3, which are located outside the factories of {{party_name}}. Local Applications: IT applications used by {{party_name}} and implemented on the local Servers. {{party_name}} is responsible for these applications, which are listed in {{party_name}}. Data: The data or information belonging to the {{party_name}} saved on magnetic support or others, and that is subject to computer treatment. Source: {{party_name}}, {{party_name}}, {{effective_date}} ANNEX 2: SERVICES AND {{party_name}} in Measuring periods when {{party_name}} Availability South African {{amount}} availability {{effective_date}} the network is not work schedule available {{party_name}} in the 15 minutes following the Measuring the period {{party_name}} reports of network Workdays in fault report as well as an account {{amount}} of faults between the beginning and server infrastructure South African 8H-20H when the problem has been solved. reported in the {{effective_date}} and the end of the problems work schedule {{party_name}} what alert, how and who time period problem, and fault communicates it. reporting Workdays in Measuring periods when {{party_name}} African {{amount}} availability {{effective_date}} the application is not Availability work schedule available {{party_name}}: less than two South {{amount}} of requests {{party_name}} response times South African 8H-20H African working hours solved in the time {{effective_date}} 2 for each request work schedule period Ø Blocking Bug: ● Consideration and response: less than two South African working hours ● Solution or work-around: less than one South African Workdays in workday {{amount}} of requests Measuring the response {{party_name}} African 8H-20H solved in the time {{effective_date}} times for encountered {{party_name}} Bug: work schedule period problems ● Consideration and response: less than three South African workdays ● Solution or work-around: set out by the requestor Measuring periods when {{party_name}} 7d/7d {{amount}} availability the electronic mail service Availability is not available Measuring periods when {{party_name}} 7d/7d {{amount}} availability {{party_name}} is not available Source: {{party_name}}, {{party_name}}, {{effective_date}} ANNEX 3: INVENTORY OF SERVERS USED BY SILICON SMELTERS Local or {{party_name}} Servers Functionality Priority Server Responsibility {{party_name}} of commercial and financial flow High Central {{party_name}} SMTP.{{party_name}}.ES {{party_name}} of electronic mail High Central {{party_name}} POP.{{party_name}}.ES Delivery of electronic mail High Central {{party_name}} {{party_name}} WEB application, access to electronic mail service and sharing of Medium Central {{party_name}} documents and information Source: {{party_name}}, {{party_name}}, {{effective_date}} ANNEX 4: INVENTORY OF APPLICATIONS USED BY SILICON SMELTERS Local or Central Server and Application Name of Application Functionality Priority Server Management Responsibility {{party_name}} of commercial and financial flow High Central {{party_name}} Email service {{party_name}} and reception of electronic mail High Central {{party_name}} {{party_name}} WEB application, access to electronic mail service and Medium Central {{party_name}} sharing of documents and information Source: {{party_name}}, {{party_name}}, {{effective_date}}

{{party_name}} 10.13 Outsourcing {{party_name}} on Development of Miaoli Royal Resort Hotel Planning Unit: {{party_name}} {{effective_date}} Source: {{party_name}}, INC., {{party_name}} (on F-1), {{party_name}} {{party_name}} (hereinafter referred to as {{party_name}}) and the Covenanter: {{party_name}} (hereinafter referred to as {{party_name}}) hereby agree to establish the following terms and conditions with regard to the development of Miaoli Royal Resort Hotel: Article {{party_name}}. {{party_name}} Range The base of the project is located on Lot No. 19 and so on in the Section of Laotianliao, Touwu Township, Miaoli County (refer to the attached map for more details) with an area about 29 hectares. Article III. Outsourced Work Outsourced work regarding this {{party_name}} is stated below: Part I: Establishment of Architectural Development Plan and Business Plan I. Establishment of documents and drawing relevant to {{party_name}} Business Plan II. Attendance of Concerned Work Coordination Meeting 1. Attendance of relevant review meetings and presentations 2. Reply to relevant consultations and revision of the development plan Part II: Development of Soil and Water Conservation Plan I. Establishment of documents and drawing relevant to the soil and water conservation plan. 1. Trunk sewer, calculation on water control and treatment and relevant design drawings. 2. Design of disasters prevention facilities during construction. 3. Design of desilting and detention basin. 4. Designs and drawings relevant to soil and water conservation. II. Attendance of Concerned Work Coordination Meeting 1. Attendance of review meetings and presentations 2. Reply to relevant consultations and revision of scheme drawings associated with soil and water conservation. III. {{party_name}} and verification relevant to land preparation and water discharge of the project. Source: {{party_name}}, INC., {{party_name}} (on F-1), {{party_name}} Part III: {{party_name}} Report I. Program on runoff of Waste Water And Pollution Reduction on the Construction Site. II. Implementation Plan for Environmental Protection. III. Environmental Monitoring (Monitoring Report prior to {{party_name}}) IV. Establishment of Environmental Impact Statement And Assessment Report Part IV: Establishment of Documents Relevant to Change of Land Usage (I) Establishment of Documents and Drawings Relevant to Change of Land Usage. (II). Attendance of Concerned Work Coordination Meeting 1. Attendance of relevant review meetings and presentations. 2. Reply to relevant consultations and plan revision. Part V: Establishment of Documents and Drawings Relevant to {{party_name}}, Concepts and Calculations on Landscaping II. Planting Scheme & Relevant Design Drawings III. {{party_name}} on Green Cover Rate Part VI: Planning, Design and Monitoring on Miscellaneous Works I. Basic Design. II. Establishment of {{party_name}} to Miscellaneous Works 1. Trunk sewer, calculation on water control and treatment and relevant design drawings 2. Design of disasters prevention facilities during construction 3. Design of desilting and detention basin 4. Designs and drawings relevant to miscellaneous works III. Attendance of {{party_name}}. Attendance of project review meetings and presentations 2. Reply to relevant consultations and revision of relevant documents and drawings. IV. {{party_name}} and {{party_name}} of Miscellaneous Works Relevant to the {{party_name}} (including signing and verification of geological technicians) V. {{party_name}} VI. Submitting documents for obtaining miscellaneous license, providing structural design and signing and verification relevant to the miscellaneous works. Part VII: Planning and Design of Relevant Buildings and {{party_name}} I. Planning & Design of Relevant Buildings. Source: {{party_name}}, INC., {{party_name}} (on F-1), {{party_name}} II. Coordination on geological drilling and survey and arrangement of building structure, sewage treatment, water and electricity utility, fire protection, telecommunications and electrical and mechanical systems etc. for various professional technicians pursuant to relevant laws and regulations. III. Construction Drawings (involving building structure, interior decoration, water supply and drainage and electricity, telecommunication, monitoring, fire protection and air conditioning system). IV. Assistance in {{party_name}}. V. Submitting of Construction License and Structure, Water, Electricity and Fire Protection Design for Reviewing, Signing and Verification. VI. Monitoring on Major Construction {{party_name}}. VII. {{party_name}} (Survey on Major {{party_name}}). VIII. Solving Any {{party_name}} to the Construction. IX. Other Items Agreed by the Two Parties Herein. Article IV. Service Fee The fees for services mentioned in Part I to Part VI are {{party_name}} (({{party_name}}Y TWELVE MILLION ONLY) in total and the fees for planning and design of the buildings and construction monitoring shall be calculated based on the ratio of {{amount}} of the legal construction cost hereof. Should {{party_name}} require a comprehensive modification on the development plan of the project outsourced and any subsequent extra cost occur in {{party_name}}; {{party_name}} shall bear the corresponding extra service fee. Article V. Payment Method With regard to the payment method regarding the project herein, {{party_name}} shall remit relevant cashes into the account designated by {{party_name}} by stages as per the following conditions: Stage 1: The service fee of NTD 1.2 million ({{party_name}}Y ONE MILLION AND TWENTY THOU{{party_name}}ND ONLY) shall be paid upon signing of the {{party_name}} herein. Stage 2: The service fee of NTD 1.2 million ({{party_name}}Y ONE MILLION AND TWENTY THOU{{party_name}}ND ONLY) shall be paid upon completion of {{party_name}}. Stage 3: The service fee of NTD 1.2 million ({{party_name}}Y ONE MILLION AND TWENTY THOU{{party_name}}ND ONLY) shall be paid after the soil and water conservation plan and relevant drawings are filed in the county government. Stage 4: The service fee of NTD 1.2 million ({{party_name}}Y ONE MILLION AND TWENTY THOU{{party_name}}ND ONLY) shall be paid after the {{party_name}} Report and relevant drawings are filed in the county government. Source: {{party_name}}, INC., {{party_name}} (on F-1), {{party_name}} Stage 5: The service fee of {{amount}} ({{party_name}}Y ONE MILLION ONLY) shall be paid after the {{party_name}} Report is adopted. Stage 6: The service fee of {{amount}} ({{party_name}}Y THREE MILLION ONLY) shall be paid after the Development Plan is adopted. Stage 7: The service fee of {{amount}} ({{party_name}}Y ONE MILLION ONLY) shall be paid after change of the non-urban land usage is completed. Stage 8: The service fee that is {{amount}} of the legal construction cost shall be paid after documents and drawings for applying for the construction license of relevant buildings and the application is submitted to the competent authority. Stage 9: The service fee that is {{amount}} of the legal construction cost shall be paid upon submitting the construction starting application to the competent authority. Stage 10: The final service fee shall be paid in a lump sum upon the completion of the structure of relevant buildings and submitting the usage license application to the competent authority. In case the {{party_name}} cannot be performed due to any reason other than the architect herein, the client agrees the fees paid will not be refunded. In case the {{party_name}} cannot be performed due to the architect herein, the architect shall refund the fees paid in full without taking any interest to the client. Article VI. Exclusions The service fee shall not include the fees for land measurement and boundary identification, geological drilling, meeting relevant land administration regulations, air pollution prevention, meeting relevant construction regulations, security system monitoring, scrivener service, deposit of soil and water conservation, review of the competent authority, attendance of concerned experts and scholars and meeting relevant administrative regulations. Article VII. Term Planned {{party_name}} shall make the most economical and effective arrangement for {{party_name}} with respect to the project based on the principle of alignment with the plan progress of {{party_name}}. The term planned is stated as following: {{party_name}} survey and measurement, geological drilling and program evaluation ({{amount}}. Establishment of architectural development plan and business plan (about 2.0 months); III. Development of soil and water conservation plan (about 2.0 months); IV. Establishment of environmental impact assessment report (about 8.0 months); V. Review of development plan (containing soil and water conservation plan and environmental impact assessment report) (about 4 - 6 months); Source: {{party_name}}, INC., {{party_name}} (on F-1), {{party_name}} VI. Miscellaneous works review (about 2 - 4 months); VII. Change of usage zoning and category of the land (about 2 - 4 months); VIII. Application for miscellaneous license ({{effective_date}}) IX. Application for construction license (including review on green construction materials and barrier-free facilities) ({{effective_date}}) Article VIII. Duties of {{party_name}} {{party_name}} shall provide the following data during the term mentioned above: {{party_name}} of rights relevant to the land. I{{party_name}} required by {{party_name}} and can be provided by {{party_name}}. (I) Basic data that must be provided in accordance with relevant regulations: 1. Name and business address of the developer; 2. Full name, address and ID card number of the person in charge; 3. Purpose and content of the development. Article IX. Duties of {{party_name}} I. {{party_name}} shall follow all instructions of {{party_name}} and ensure all plans and designs of the project to meet relevant construction laws and regulations. II. {{party_name}} shall take on a professional attitude for various services mentioned in Article III of the {{party_name}}, maintain benefits and interests of {{party_name}} all the time and adopt the most economical option under the precondition of safety and reliability. III. {{party_name}} is obligatory to report the latest progress and completed content to {{party_name}}. Article X. Special Terms I. With regard to the payment of all fees for professional services, the person appointed shall designate relevant professional institutions and pay the fees directly to them and the service fees due will be deducted after the payment foregoing is made. II. Any other items not specified in the {{party_name}} may be negotiated and formulated by the both Parties herein separately. Source: {{party_name}}, INC., {{party_name}} (on F-1), {{party_name}} Article XI. Disputes Resolving Both parties herein agree to resolve any dispute regarding interpretation of the {{party_name}} in the following methods: {{party_name}} both Parties be unable to reach an agreement within {{effective_date}} through negotiation, they may apply for an arbitration in Miaoli County and the arbitration result shall be compulsory. I{{party_name}} either {{party_name}} herein initiate a legal proceeding for revoking any arbitration result regarding the {{party_name}}, both Parties herein agree to take {{party_name}} of Taiwan as the competent court of first instance pursuant to the laws of the {{party_name}}.. Article XII. The {{party_name}} shall be made in duplicate and {{party_name}} and {{party_name}} shall hold a copy respectively in witness thereof. Covenanters {{party_name}}: The HUANG JIA Country CLUB and {{party_name}} Address: {{party_name}}, No. 106, Zhouzi Street, Neihu District, Taipei City Tel: 02-26582502 {{party_name}}:{{party_name}} Unified No: 95822673 Address: No. 1, {{party_name}}, No. 575, Jinhwa Road, Bei District, Taichung City Tel: 04-22373588 Fax: 04-22373388 {{effective_date}} Source: {{party_name}}, INC., {{party_name}} (on F-1), {{party_name}}

{{party_name}} 10.29 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. {{party_name}} Outsourcing {{party_name}} Between {{party_name}} and {{party_name}} 30 {{effective_date}} Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. Table of Contents Article 1 Interpretation 7 1.1 Definitions 7 1.2 Other Definitions 11 1.3 Currency 11 1.4 Headings 11 1.5 {{party_name}} 11 1.6 {{party_name}} 12 Article 2 Term 12 2.1 Term 12 2.2 Effect of Expiration on {{party_name}}s 12 Article 3 Supply of {{party_name}} 12 3.1 Supply of {{party_name}} 12 3.2 Manufacturing {{party_name}} 13 3.3 Supply of Materials and {{party_name}} Material 13 3.4 {{party_name}}ion Capacity 15 3.5 Processing Changes 15 3.6 Monitoring of Facilities 16 3.7 Subcontracting 16 3.8 [* * *] 16 3.9 [* * *] 17 3.10 {{party_name}} Expansion 17 3.11 Supply to {{party_name}} Licensees 17 3.12 Alternative Supply 17 Article 4 Forecasts 18 4.1 {{party_name}}s 18 4.2 Long Term Forecasts 18 CONFIDENTIAL Page 2 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. Article 5 Testing and Samples 19 5.1 Release Testing 19 5.2 Additional Release Testing 19 5.3 {{party_name}} 19 5.4 Stability Testing 20 5.5 Reference Standards {{amount}} 20 Article 6 {{party_name}}s 20 6.1 Placement of {{party_name}}s {{amount}} 20 6.3 Delays 21 6.4 Cancellation of {{party_name}}s 21 6.5 Material Failure of Supply 21 6.6 {{party_name}} 21 {{party_name}} 22 7.1 Storage of {{party_name}} 22 7.2 {{party_name}} 22 7.3 Documentation 23 7.4 {{party_name}} 23 Article 8 Acceptance of Shipments 23 8.1 Acceptance of Shipments 23 8.2 Dispute of Rejected {{party_name}} 24 8.3 Remedies 24 Article 9 Fees 25 9.1 Fees 25 9.2 Adjustments to Fees 25 9.3 {{party_name}} 26 CONFIDENTIAL Page 3 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. Article 10 Invoicing and Payment 26 10.1 Issuance of Invoices 26 10.2 Invoice Contents 26 10.3 Delay of {{party_name}} {{party_name}} 27 11.1 {{party_name}} 27 11.2 No Grant of Rights 27 11.3 Grant of License by {{party_name}} 28 11.4 Ownership of Inventions 28 11.5 Patents to Inventions 28 11.6 No Use of Trademarks 28 11.7 [* * *] 28 Article 12 Confidentiality & Publicity 29 12.1 Obligation of Confidentiality 29 12.2 Disclosure with Consent 29 12.3 Publicity 29 12.4 Disclosure Required by Law 30 12.5 {{party_name}} 30 12.6 Duration of Obligation 30 Article 13 Representations, {{party_name}} and Covenants 31 13.1 {{party_name}}, {{party_name}} and Covenants 31 13.2 {{party_name}}’s Representations, {{party_name}} and Covenants {{effective_date}} No Other Warranty 32 {{effective_date}} No {{party_name}} and Limitation of Liability 33 Article 14 Indemnification 33 14.1 Indemnification of {{party_name}} 33 CONFIDENTIAL Page 4 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. 14.2 Indemnification of {{party_name}} 33 14.3 {{party_name}} Indemnity 34 14.4 Indemnification Procedure 34 Article 15 Insurance 35 15.1 Insurance Coverage 35 15.2 Evidence of Insurance 35 Article 16 Legal and Regulatory 35 16.1 Compliance with Laws 35 16.2 {{party_name}} 36 16.3 Notice of Reports 36 16.4 Drug Master {{party_name}} 16.5 Compliance with Regulatory Standards 36 16.6 Inspection 36 Article 17 Recalls 37 17.1 Safety 37 17.2 Recalls 37 17.3 {{party_name}} 37 17.4 {{party_name}}’s Liability for Recall 37 17.5 Replacement Shipments 37 Article 18 Termination 38 18.1 Termination 38 18.2 Consequences of Termination 39 18.3 Return of Samples 40 18.4 Return of {{party_name}} 40 18.5 Survival 40 Article 19 Miscellaneous {{effective_date}} Assignment; Inurement 41 CONFIDENTIAL Page 5 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. 19.2 Change of Control 41 19.3 Counterparts 41 19.4 Dispute Resolution 41 19.5 Force Majeure 42 19.6 Performance 42 19.7 Further Assurances 42 19.8 Independent {{party_name}}ors 42 19.9 Injunctions 43 19.10 Notices {{effective_date}} Entire {{party_name}} 44 19.12 Severability 44 19.13 Waiver 44 CONFIDENTIAL Page 6 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. THIS AGREEMENT (this “{{party_name}}”), dated {{effective_date}} ({{party_name}}”), is BETWEEN: {{party_name}}, a company having a place of business at 75 Park Plaza, {{party_name}}, Boston, MA 02116, U{{party_name}} (“{{party_name}}”) AND: {{party_name}}, a company having a place of business at Hauptstrasse 171, {{party_name}}, Switzerland (“{{party_name}}” and, collectively with {{party_name}}, the “Parties”, and each, a “{{party_name}}). WHEREAS: A. {{party_name}} is the owner of certain technology and patent rights regarding the {{party_name}} (as defined herein) having the description set out in {{party_name}} A (Description of {{party_name}}) and {{party_name}} B (Chemical Synthesis); B. {{party_name}} has filed / intends to file for approval with {{party_name}} and/or its foreign equivalents, an {{party_name}} (“{{party_name}}”) and {{party_name}} (“{{party_name}}”), and/or the foreign equivalents thereof, for certain formulations containing the {{party_name}}; {{party_name}} is engaged in the business of performing contracted process development, Manufacturing and supply services of active pharmaceutical ingredients (“APIs”) and intermediates; and D. {{party_name}} desires that {{party_name}} in bulk quantities, and {{party_name}} desires to perform such services, each on the terms and conditions set out in this {{party_name}}. NOW THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: Article 1 Interpretation 1.1 Definitions In this {{party_name}}, in addition to words and phrases defined where they are used, the following words and phrases shall have the following meanings: a) “Affiliate” of a {{party_name}} shall mean any entity, directly or indirectly, controlling, controlled by, or under common control with a {{party_name}}. For purposes of this definition, “controlling” (including, “controlled by” and “under CONFIDENTIAL Page 7 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. common control”) shall mean: (a) ownership of {{amount}} ({{amount}}) of the equity capital or other ownership interest in or of an entity; (b) the power to control or otherwise direct the affairs of an entity; (c) in the case of non-stock organizations, the power to control the distribution of profits of an entity; or (d) such other relationship as, in fact, results in actual control over the management, business, and affairs of an entity; b) “{{party_name}}” means this Supply {{party_name}} for the {{party_name}}, including all {{party_name}} attached hereto; c) “{{party_name}}” means any applicable law, statute, rule, regulation, order, judgment or ordinance of any governmental or regulatory authority or agency; d) “{{party_name}}” means {{party_name}}, {{party_name}} other equivalent governmental or regulatory authorities or agencies and any successors thereto; e) “Business Day” means any day on which banking institutions in Boston, Massachusetts and Bubendorf, Switzerland are open for business; f) “Campaign” means a schedule of one or more discrete batches of {{party_name}} in sequence by {{party_name}} without pausing to change over to manufacture of any other product; g) “cGMP Requirements” means the current {{party_name}} standards required under ICH Q7A guideline and/or any similar standards of applicable governmental and/or regulatory authorities as defined in the Quality {{party_name}}; h) “Change of Control” means any transaction or series of transactions wherein (a) the voting securities of {{party_name}} outstanding immediately prior thereto cease to represent {{amount}} ({{amount}}) of the combined voting power of the surviving entity immediately after such transaction or transactions; (b) the stockholders or equity holders of {{party_name}} approve a plan of complete liquidation of {{party_name}}, or an agreement for the sale or disposition by {{party_name}} of all or substantially all of {{party_name}}’s assets, other than to an Affiliate; (c) a Third {{party_name}} becomes the beneficial owner of {{amount}} ({{amount}}) or more of the combined voting power of the outstanding securities of {{party_name}}; or (d) substantially all of {{party_name}}’s business or assets which relate to this {{party_name}} are sold or otherwise transferred to a Third {{party_name}}; i) “Chemical Synthesis” means established and reliable execution of chemical reactions in order to produce the “{{party_name}}” by applying chemical and physical manipulations usually involving one or more reactions; j) “{{party_name}}” means all written information and data provided by the Parties to each other hereunder and identified as being “Confidential” and provided to the recipient, except that the term “{{party_name}}” shall not apply to any information or any portion thereof which: (i) was known to the recipient or any of its {{party_name}}, as evidenced by its written records, before receipt thereof under this {{party_name}}; (ii) is disclosed to the recipient or any of its {{party_name}}, without obligations of confidentiality, during the Term by a Third {{party_name}} who has the right to make such disclosure; CONFIDENTIAL Page 8 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. (iii) is or becomes part of the public domain through no breach of this {{party_name}} by the recipient; or (iv) the recipient can demonstrate through competent written records is independently developed by or for the recipient or any of its {{party_name}} by individuals or entities who have not had access to the information disclosed under this {{party_name}}. The {{party_name}} may include, without limitation, data, know-how, formulae, processes, designs, sketches, photographs, plans, drawings, specifications, samples, reports, studies, data, findings, inventions, ideas, production facilities, machines, production capacities, prices, market share, research and development projects, and other market data. For the purposes of this {{party_name}}, Master {{party_name}} shall be deemed the {{party_name}} of {{party_name}} and the {{party_name}} Specifications shall be deemed the {{party_name}} of {{party_name}}; k) “{{party_name}} Licensee” means any Third {{party_name}} to whom {{party_name}} grants a license or a right to research, develop, make, have made, use, sell, have sold, import, export or otherwise exploit a {{party_name}} or {{party_name}} {{party_name}}; l) “{{party_name}} Material” means the compound satisfying the {{party_name}} Material Specification; m) “{{party_name}} Material Specifications” means the specifications for the {{party_name}} Material set forth in the Quality {{party_name}}, as such may be amended from time to time in accordance with its terms; n) “{{party_name}} {{party_name}}” means any pharmaceutical product owned, controlled or sold by {{party_name}}, its {{party_name}} or {{party_name}} Licensees that incorporates or is derived from a {{party_name}}; o) “{{party_name}} Technology” means: [* * *]; p) “Drug Master File” or “{{party_name}}” means a submission to {{party_name}} that provides detailed information about facilities, processes or articles used in the {{party_name}}, processing, packaging and storing of a drug or excipient, among others, in order to obtain appropriate {{party_name}} approval for the production for that drug; q) “EMEA” means {{party_name}} and any successors thereto; r) “{{party_name}}” means {{party_name}} and any successors thereto; s) “FD&C Act” means {{party_name}}, as the same may be amended or supplemented from time to time; t) “Fees” means the fees specified in {{party_name}} C, as may be amended by the Parties in accordance with this {{party_name}}; CONFIDENTIAL Page 9 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. u) “Improvements” means, in relation to any {{party_name}}, any and all versions, adaptations, modifications, improvements, enhancements, changes, revisions, translations and derivative works (whether complete or incomplete), of, to, in or based upon such {{party_name}}; v) “{{party_name}}” means anything that is protected by any Rights in and to any and all patents, trade-marks, copyrights, industrial designs, {{party_name}}, know-how and processes, and all other intellectual and industrial property Rights whatsoever and world-wide (whether registered or unregistered and including Rights in any application for any of the foregoing); w) “{{party_name}},” “{{party_name}}d” or “Manufacturing” means all activities involved in the production of {{party_name}}s to be supplied to {{party_name}} or its {{party_name}} hereunder, including the preparation, formulation, finishing, testing, storage and packaging for shipment of {{party_name}}s and the handling, storage and disposal of any residues or wastes generated thereby; x) “Manufacturing Process” means the activities set out in (a) this {{party_name}}, (b) {{party_name}} {{party_name}} and (c) {{party_name}}’s standard operating procedures for the Manufacturing, characterization and testing, and bulk packaging and storage of the {{party_name}}; y) “Master {{party_name}}” means the complete detailed Manufacturing and control instructions and specifications for {{party_name}}, as defined by the applicable validation protocol and cGMP Requirements, as may be amended from time to time; in accordance with cGMP Requirements, or by mutual agreement of both {{party_name}} and {{party_name}}; z) “Materials” means any and all materials, reagents, chemicals, compounds, physical samples, models, specimens and any other similar physical substances that are used in the {{party_name}} of the {{party_name}} except for {{party_name}} Materials, including processes and activities leading up to and peripheral to the {{party_name}} of the {{party_name}}; aa) “{{party_name}}” means the compound product as described in {{party_name}} A satisfying the {{party_name}} Specifications; bb) “{{party_name}} Specifications” means the specifications for the {{party_name}} set forth in the Quality {{party_name}}, as such may be amended from time to time in accordance with its terms; cc) “Quality {{party_name}}” shall mean that certain Quality {{party_name}} Relating to {{party_name}} Manufacturing {{party_name}} by and between {{party_name}} and {{party_name}}, dated [* * *]; dd) “Recall” means any action by {{party_name}}, {{party_name}} or any of their respective {{party_name}}, to recover possession of the {{party_name}} or finished products containing the {{party_name}} shipped to Third Parties. “Recalled” and “Recalling” shall have comparable meanings; ee) “Rights” shall mean any and all proprietary, possessory, use and ownership rights, titles and interests (whether beneficial or legal) of all kinds whatsoever, howsoever arising, world-wide and whether partial or whole in nature; CONFIDENTIAL Page 10 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. ff) “Seizure” means any action by an {{party_name}} in any jurisdiction, to detain or destroy any {{party_name}} or any intermediate or finished products containing the {{party_name}} or prevent release of the {{party_name}} or finished products containing the {{party_name}}. “Seized” and “Seizing” shall have comparable meanings; gg) “{{party_name}}” refers to any activities undertaken by {{party_name}} relating to the {{party_name}}, as referenced in Section 6.6 ({{party_name}}); hh) “{{party_name}} Technology” means, to the extent such is not {{party_name}} Technology: [* * *]; ii) “Term” means the Initial Term and the Renewal Term, if applicable; jj) “{{party_name}}” means the United States of America and its territories and possessions and any other countries in the world added to the definition of “{{party_name}}” pursuant to {{party_name}}) “Third {{party_name}}” means any party other than a {{party_name}} to this {{party_name}} or an Affiliate of a {{party_name}} to this {{party_name}}; and ll) “Yield” means, with respect to any batch of {{party_name}} manufactured by {{party_name}} under this {{party_name}}, a percentage equal to the amount of {{party_name}} Material contained in such batch of {{party_name}} delivered and accepted by {{party_name}} under this {{party_name}} divided by the amount of {{party_name}} Material used in {{party_name}} of such batch of {{party_name}}. 1.2 Other Definitions Any words defined elsewhere in this {{party_name}} shall have the particular meaning assigned to the words. 1.3 Currency In this {{party_name}}, all references to money or payments means {{party_name}} and all payments made hereunder shall be made in that currency. 1.4 Headings The headings in this {{party_name}} are solely for convenience of reference and shall not be used for purposes of interpreting or construing the provisions hereof. 1.5 {{party_name}} The {{party_name}} attached hereto shall be deemed to form an integral part of this {{party_name}}. In the event of a conflict between the terms and conditions set out in this {{party_name}} and the terms and conditions set out in any {{party_name}} hereto, the terms and conditions set out in this {{party_name}} shall govern. CONFIDENTIAL Page 11 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. 1.6 {{party_name}} This {{party_name}} shall be governed by and construed in accordance with the substantive Laws of the [* * *], excluding any rules of conflicts of laws that would apply the substantive laws of any other jurisdiction. Article 2 Term 2.1 Term [* * *] This {{party_name}} shall commence on {{party_name}} and shall be valid until the [* * *] (the “Initial Term”). Both Parties shall use reasonably diligent efforts to come to a subsequent long-term agreement, including good faith negotiations regarding minimum volume-based {{party_name}} commitments from {{party_name}} to {{party_name}}, no later than [* * *] to replace this {{party_name}} and serve as a long-term supply agreement between the Parties. Should the Parties have not agreed to the following agreement by [* * *], this {{party_name}} shall automatically stay in force for a maximum of [* * *] (unless otherwise mutually agreed by the Parties or as otherwise set forth in {{effective_date}})) or until the Parties have signed the follow-on agreement (the “Renewal Term”). 2.2 Effect of Expiration on {{party_name}}s For the avoidance of doubt, any signed {{party_name}} which has not been completed at the date of expiry shall continue in effect unless cancelled in accordance with Section 6.4 or Article 18. For further avoidance of doubt, the terms and conditions of this {{party_name}} shall remain applicable to any such signed {{party_name}} which continues in effect. Article 3 Supply of {{party_name}} 3.1 Supply of {{party_name}} a) During the Term, {{party_name}} shall {{party_name}} the {{party_name}} and perform all {{party_name}} at its facilities located at Bubendorf, Switzerland and at Neuland, Switzerland (such facilities, the “Facilities” and each, a “{{party_name}}”). {{party_name}} will supply to {{party_name}} or {{party_name}}’s designee, the {{party_name}}, {{party_name}}d in accordance with the accepted {{party_name}} placed by {{party_name}}, Master {{party_name}}, the {{party_name}} Specifications, the Quality {{party_name}} and cGMP Requirements and, subject to Section 3.1(b), in such quantities as ordered by {{party_name}} in {{party_name}}s submitted pursuant to Section 6.1 and accepted pursuant to Section 6.2. CONFIDENTIAL Page 12 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. b) [* * *] c) [* * *] d) In the event the {{party_name}} manufactured and delivered to {{party_name}} under a {{party_name}} is less than [* * *] of the amount ordered by {{party_name}} under such {{party_name}} or if {{party_name}} otherwise reasonably requests, [* * *]. d) For clarity, nothing in this Section 3.1 limits {{party_name}}’s liability under this {{party_name}} or under law, including liability for negligence, willful misconduct and failure to comply with {{party_name}} Specifications; [* * *]. 3.2 Manufacturing {{party_name}} {{party_name}} will make available its labor, equipment and Facilities for the {{party_name}} and characterization of the {{party_name}}, including in-process and quality control analyses, release testing, storage and bulk packaging of the {{party_name}}, and shipping of the {{party_name}}, in accordance with the terms and conditions of this {{party_name}}. 3.3 Supply of Materials and {{party_name}} Material a) Materials i. {{party_name}} shall, at its cost, be responsible for the purchase, planning, supply, control, testing, release and compliance of all Materials (other than {{party_name}} Materials unless expressly otherwise set forth in this {{party_name}}) required for the {{party_name}} of the {{party_name}} and performance of {{party_name}} under accepted {{party_name}}s. ii. {{party_name}} shall ensure that all Materials (other than {{party_name}} Material unless expressly otherwise set forth in this {{party_name}}) used in the {{party_name}} of the {{party_name}} and performance of {{party_name}} shall comply with the specifications mutually agreed by the Parties in writing and applicable requirements of the Quality {{party_name}}. iii. {{party_name}} shall test and inspect all Materials as set forth in the Quality {{party_name}} and {{party_name}}’s standard incoming inspection and testing procedures, which at a minimum will include appearance and identity testing. b) {{party_name}} Material i. {{party_name}} or its designee (for which {{party_name}} is responsible) shall, at its cost, be responsible for the planning, supply, control, testing, release and compliance of all {{party_name}} Materials supplied to {{party_name}} that are required for the {{party_name}} of the {{party_name}} and performance of {{party_name}} under accepted {{party_name}}s. {{party_name}} shall ensure that all {{party_name}} Materials meet the {{party_name}} Material Specifications. CONFIDENTIAL Page 13 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. ii. {{party_name}} or its designee (for which {{party_name}} is responsible) shall, at its cost, be responsible for the qualification of suppliers of {{party_name}} Materials. iii. {{party_name}} or its designee (for which {{party_name}} is responsible) shall ensure that all {{party_name}} Materials used in the {{party_name}} of the {{party_name}} and performance of {{party_name}} shall meet applicable requirements set forth in the Quality {{party_name}}. iv. {{party_name}} shall test and inspect all {{party_name}} Materials in accordance with the Quality {{party_name}} and {{party_name}}’s standard incoming inspection and testing procedures. {{party_name}} shall also independently release {{party_name}} Materials (but {{party_name}} shall not use any {{party_name}} Materials that have not also been released by {{party_name}}). v. Upon receipt of a {{party_name}} from {{party_name}}, {{party_name}} will inform {{party_name}} of the latest delivery date required for {{party_name}} Materials [* * *]. {{party_name}} will use commercially reasonable efforts to coordinate delivery of {{party_name}} Materials by that date according to [* * *]. vi. If {{party_name}} is unable to deliver {{party_name}} Materials by the date required by {{party_name}}, this will be promptly communicated to {{party_name}}. {{party_name}} will use commercially reasonable efforts to reallocate capacity and accommodate the planned Campaign at {{effective_date}}. [* * *] {{party_name}} will be released from its obligation under the relevant {{party_name}} and any associated penalties regarding delivery date for the corresponding {{party_name}}. In the event of any such delay in the delivery of {{party_name}} Materials to {{party_name}}, the Parties shall negotiate in good faith and agree upon a revised schedule for the supply of {{party_name}}s to {{party_name}} or its designee, which revised schedule shall be binding on {{party_name}} in accordance with this {{party_name}}. vii. In the event that {{party_name}} Materials delivered to {{party_name}} are found by {{party_name}} to be non-conforming to the {{party_name}} Material Specifications at the time of delivery of such {{party_name}} Materials to {{party_name}} and {{party_name}} challenges this finding, the Parties shall conduct a joint investigation. If {{party_name}} and {{party_name}} are unable to resolve the issue of non-compliance then a sample of the relevant {{party_name}} Material will be submitted to an independent laboratory reasonably acceptable to both Parties for testing against the {{party_name}} Material Specifications, and determination whether or not the {{party_name}} Material did not comply with the {{party_name}} Material Specifications at the time of delivery to {{party_name}}. The test results of the independent laboratory testing shall be final and binding upon {{party_name}} and {{party_name}}, and the fees and expense of such laboratory testing and the out-of-pocket costs reasonably incurred by the Parties in the joint investigation shall be [* * *] In such event, except as set forth in Section 3.3(b)(vi), {{party_name}} shall be released from its obligation with respect to the relevant {{party_name}} and any associated penalties regarding a delayed delivery date for the corresponding {{party_name}} under such {{party_name}}. In the event that {{party_name}} delivers any such non-conforming {{party_name}} Materials, the Parties shall negotiate in good faith and agree upon a revised schedule for the supply of {{party_name}}s to {{party_name}} or its designee, which revised schedule shall be binding on {{party_name}} in accordance with this {{party_name}}. viii. {{party_name}} will provide {{party_name}} with a {{party_name}}, a {{party_name}}/{{party_name}} statement and {{party_name}}, data on the chemical and physical properties, toxicity, and handling, storing, and shipping information for any {{party_name}} Materials (MSDS or equivalent) and any other information that is necessary for the safe handling and transportation of {{party_name}} Materials. {{party_name}} shall update all of such information provided to {{party_name}} after such updated information becomes available or known to {{party_name}}. CONFIDENTIAL Page 14 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. Following receipt of {{party_name}} Materials from {{party_name}} and until the delivery of {{party_name}} containing such {{party_name}} Materials, {{party_name}} shall bear the risk of any loss of or damage to such {{party_name}} Materials resulting from [* * *]. {{party_name}} shall retain exclusive control over {{party_name}} Materials and shall not transfer any portion of them to any Third {{party_name}} without the prior written consent of {{party_name}}. {{party_name}} shall identify {{party_name}} Materials at all times as {{party_name}} property and shall segregate same from other substances except as needed for the {{party_name}} of the {{party_name}} and performance of the {{party_name}}. {{party_name}} shall not take any action inconsistent with {{party_name}}’s ownership interest in {{party_name}} Materials, including but not limited to, {{party_name}} shall keep {{party_name}} Materials free and clear of any liens, encumbrances, or security interests resulting from the actions or omissions of {{party_name}} or its {{party_name}} and, in the event of any such liens, encumbrances, or security interests, {{party_name}} shall promptly remove same at its sole expense. 3.4 {{party_name}}ion Capacity {{party_name}} agrees to provide to {{party_name}} all such facility and Manufacturing capacity to perform {{party_name}} as required to meet the {{party_name}} requirements as described in the then-current {{party_name}} (as defined below). {{party_name}} agrees that it shall provide to {{party_name}} at least [* * *] prior written notice of any scheduled shutdown at any {{party_name}} that may impact {{party_name}}’s ability to {{party_name}} and timely deliver the {{party_name}} to {{party_name}} under this {{party_name}}, [* * *]. For the avoidance of doubt, {{party_name}} confirms that it has the capacity to deliver [* * *], or such adjusted amount as mutually agreed by the Parties. Batch size and {{effective_date}} capacity could be adjusted in the future by mutual agreement of the Parties based on results of ongoing scale up work. 3.5 Processing Changes a) {{party_name}} shall not make any material changes to {{party_name}}, starting materials, {{party_name}} {{party_name}} or {{party_name}} Specifications for the {{party_name}} of the {{party_name}} except in accordance with the Quality {{party_name}}. For clarity, formatting changes in the documentation related to {{party_name}} {{party_name}} shall not be deemed a “material” change under this Section 3.5(a). b) {{party_name}} (or {{party_name}}, if changes are necessitated by {{party_name}}) may request reasonable changes to {{party_name}}, {{party_name}} {{party_name}}, the {{party_name}} Specifications, storage, testing or analytical methods or any starting materials for the {{party_name}} of the {{party_name}} [* * *]. The notice of any CONFIDENTIAL Page 15 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. such change by {{party_name}} shall comply with the cGMP documentation system and standard operating procedures maintained by {{party_name}} at the Facilities. No material modifications or additions to the machinery, equipment and other fixed assets used by {{party_name}} in the manufacture and supply of the {{party_name}} to {{party_name}} shall be required without the consent of {{party_name}}, which consent may be granted or withheld in {{party_name}}’s sole discretion. c) In the event of a change to {{party_name}}, {{party_name}} {{party_name}} or the {{party_name}} Specifications, the relevant documents and related {{party_name}} to this {{party_name}} will be revised accordingly. d) All operational Master {{party_name}}s and standard operating procedures utilized by {{party_name}} are in the German language. Any requirement by {{party_name}} for translation of such records will be billed at cost. 3.6 Monitoring of Facilities {{party_name}} shall have the right to have a representative present at each {{party_name}} to observe the performance of {{party_name}} by {{party_name}} during normal business hours with at least [* * *] advance notice. {{party_name}} shall have the right to reasonably restrict such observation access to prevent undue interference with {{party_name}}’s business operations or compromise {{party_name}}’s confidentiality obligations to Third Parties; provided, however, {{party_name}}’s observation access shall be absolute with regard to {{party_name}}. As such it is {{party_name}}’s obligation to segregate Third {{party_name}} documents and materials from {{party_name}}’s documents and materials and {{party_name}} will not be restricted from observing any part of {{party_name}}’s Manufacturing Process and related documentation. 3.7 Subcontracting {{party_name}} shall obtain {{party_name}}’s prior written approval, in accordance with the Quality {{party_name}}, to use a subcontractor to perform services under this {{party_name}}, such approval not to be unreasonably withheld, conditioned or delayed. Any and all such contractors shall perform such services in accordance with the terms and conditions of this {{party_name}}, and {{party_name}} shall remain liable for the performance of its obligations under this {{party_name}}. {{party_name}} may use the Third {{party_name}} suppliers set forth in {{party_name}} of the Quality {{party_name}} for such specific activities set forth opposite their respective name(s) in such {{party_name}}. It is hereby agreed that {{party_name}} may authorize the use of additional Third {{party_name}} suppliers under this {{party_name}} in accordance with the Quality {{party_name}}. {{party_name}} agrees to use the Third {{party_name}} suppliers identified, as applicable, in {{party_name}} of the Quality {{party_name}} as the exclusive suppliers of starting materials for the {{party_name}} Manufacturing Process and any deviation from said supply sources requires the prior written approval of {{party_name}}, in accordance with the Quality {{party_name}}, such approval not to be unreasonably withheld, conditioned or delayed. 3.8 [* * *] CONFIDENTIAL Page 16 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. 3.9 [* * *] 3.10 {{party_name}} Expansion At any time during the Term, {{party_name}} may provide written notice to {{party_name}} of its intent to expand the {{party_name}} under this {{party_name}} to include one or more additional countries or territories. Promptly following such notification, the {{party_name}} (as defined below) shall meet to discuss any expansion of {{party_name}}‘s Manufacturing capabilities necessitated by such expansion in accordance with clause (b) of Section 7.4 and the Parties shall execute an amendment that (a) amends the definition of “{{party_name}}” under clause jj) of Section 1.1 to include such additional countries or territories and (b) modifies the provisions of this {{party_name}} as necessary in order to reflect the regulatory requirements of such additional countries or territories. For clarity, neither {{party_name}} shall be obligated to amend the definition of {{party_name}} at any point during the Term. 3.11 Supply to {{party_name}} Licensees In the event {{party_name}} delivers a written request to {{party_name}} requesting that {{party_name}} engage in negotiations with a {{party_name}} Licensee on the terms of a definitive agreement pursuant to which {{party_name}} would {{party_name}} and supply {{party_name}} to such {{party_name}} Licensee or a designee of a {{party_name}} Licensee, {{party_name}} shall use commercially reasonable good faith efforts to negotiate and execute such agreement on substantially the same terms of this {{party_name}} (including pricing, orders, forecasting, delivery, non-conformance, failure to supply, term and termination). 3.12 Alternative Supply At any time during the Term, {{party_name}} may elect to qualify one or more alternative Manufacturing facilities (whether owned by a Third {{party_name}}, {{party_name}} or by one of {{party_name}}’s {{party_name}}) to {{party_name}} the {{party_name}}s (each, a “Backup {{party_name}}”). {{party_name}} shall be responsible for any costs associated with qualifying Backup {{party_name}}s. [* * *]. {{party_name}} shall use commercially reasonable efforts to cooperate with the qualification of any Backup {{party_name}}, including (a) technology transfer of all {{party_name}} Technology necessary or useful for the {{party_name}} of the {{party_name}}s; provided that, to the extent that such technology and know-how constitutes {{party_name}} of {{party_name}}, it shall be subject to the provisions of Article 12 and {{party_name}}’s designated alternative supplier shall be required to enter into a confidentiality agreement with {{party_name}} containing substantially the same terms as Article 12 and (b) providing {{party_name}} and any Backup {{party_name}} with consulting services related to the {{party_name}}, quality control and quality assurance of the {{party_name}}s. Any work related to technology transfer or qualification of a second supplier shall be considered as {{party_name}} under this {{party_name}} as described in Section 6.6. For the avoidance of doubt, {{party_name}} will first prepare a customary {{party_name}} describing the {{party_name}} to be performed and the costs to {{party_name}} for the CONFIDENTIAL Page 17 of 49 Source: PARATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH {{party_name}}. approval of {{party_name}}. No {{party_name}} shall be commenced by {{party_name}} unless (a) a customary {{party_name}} relating to such {{party_name}} has been agreed, executed and delivered by both {{party_name}} and {{party_name}}; and (b) a {{party_name}} has been issued by {{party_name}} and accepted by {{party_name}} relating to such {{party_name}}, which {{party_name}} references the specific {{party_name}} and this {{party_name}}. In case of disagreement on the {{party_name}}, the Parties will enter into good faith negotiations to reach a mutually satisfactory resolution. Article 4 Forecasts 4.1 {{party_name}}s Commencing on {{party_name}}, {{party_name}} shall provide to {{party_name}} on a calendar {{effective_date}} basis on or before {{effective_date}} of each calendar quarter during the Term, a short term rolling forecast for the [* * *] period commencing on {{effective_date}} of the following calendar month (each, a “Short {{party_name}} Rolling Forecast”). Each Short {{party_name}} Rolling Forecast shall set out {{party_name}}’s reasonable and genuine estimate of the quantities of the {{party_name}} to be ordered by {{party_name}} and to be delivered by {{party_name}} under this {{party_name}} for the following [* * *]. (A): In case of an order volume equal or less than [* * *]: The first [* * *] of each short term rolling forecast shall be binding firm purchase orders by {{party_name}} (each a “{{party_name}}”) and the last [* * *] of each short term rolling forecast shall be non-binding, good faith estimates. {{party_name}} shall provide {{party_name}} with one or more {{party_name}}) for {{party_name}} consistent with the first [* * *] binding portion of each Short {{party_name}} Rolling Forecast, at least [* * *] in advance of the scheduled delivery dates provided in such {{party_name}}). (B): In case of order volume larger than [* * *]: The first [* * *] of each short term rolling forecast shall be binding firm purchase orders by {{party_name}} (each a “{{party_name}}”) and the last [* * *] of each short term rolling forecast shall be non-binding, good faith estimates. {{party_name}} shall provide {{party_name}} with one or more {{party_name}}) for {{party_name}} consistent with the first [* * *] binding portion of each Short {{party_name}} Rolling Forecast, at least [* * *] in advance of the scheduled delivery dates provided in such {{party_name}}). 4.2 Long {{party_name}} Forecasts Within [* * *] after {{party_name}}, {{party_name}} shall provide to {{party_name}} a long term forecast of the estimated quantities of the {{party_name}} required by {{party_name}} from {{party_name}} during the following [* * *] (the “Long {{party_name}} Forecast”). {{party_name}} shall during the {{party_name}} provide to {{party_name}} together with the Short {{party_name}} Rolling Forecast, on a calendar quarter basis, updates of such Long {{party_name}} Forecasts for the following [* * *] (or the balance of the {{party_name}}, if shorter). For the avoidance of doubt, the first [* * *] of each Long {{party_name}} Forecast shall constitute the Short {{party_name}} Rolling Forecast of which the first [* * *], or the first [* * *], as the case may be due to the order volume, shall be binding and the remainder of the Short {{party_name}} Rolling Forecast and Long {{party_name}} Forecast shall be non-binding. CONFIDENTIAL Page 18 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Article 5 Testing and {{party_name}} a) {{party_name}} shall perform release testing of all batches of {{party_name}} prior to delivery to {{party_name}} in accordance with {{party_name}} and {{party_name}} {{party_name}}, to determine whether such batches of {{party_name}} meet the requirements set out in {{party_name}}. {{party_name}} shall be responsible for the final release of {{party_name}} prior to shipping and further processing. b) {{party_name}} shall ensure that: (i) its quality assurance department approves each batch of {{party_name}} for release promptly following successful completion of release testing done by its quality control department (in this section “promptly” means [* * *]); and (ii) its quality assurance department does not release any batch of {{party_name}} that does not meet the requirements set out in {{party_name}} without prior written consent of {{party_name}}. c) {{party_name}} shall prepare a {{party_name}} and Certificate of Conformance, setting out the results of the release testing and which shall be included with each batch of {{party_name}} shipped to {{party_name}}. d) {{party_name}} shall have the right to oversee the activities set forth in this Section 5.1 in accordance with the Quality {{party_name}}. 5.2 Additional Release Testing {{party_name}} reserves the right to conduct, in its sole discretion and at its expense, additional analytical testing on the {{party_name}}. 5.3 Retention Samples {{party_name}} shall retain and store in accordance with cGMP {{party_name}}, {{party_name}} and {{party_name}}’s internal quality standard operating procedures, retention samples of each batch of {{party_name}} {{party_name}}d under this {{party_name}}. CONFIDENTIAL Page 19 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. 5.4 Stability Testing If requested by {{party_name}}, {{party_name}} shall be responsible for performing {{effective_date}} stability testing of the {{party_name}} and shall ensure that all such testing is performed in compliance with the applicable ICH regulations (e.g. follow-up stability studies of commercially used products). Costs associated with {{effective_date}} stability testing will be quoted separately from commercial unit pricing under a separate {{party_name}} or {{party_name}}. 5.5 Reference Standards If requested by {{party_name}}, {{party_name}} shall be responsible for qualification and requalification of reference standards. Costs associated with qualification and requalification of reference standards will be quoted separately from commercial unit pricing under a separate {{party_name}} or {{party_name}}. 5.6 Preparation of Process Qualification All costs associated with the preparation of process qualification (as but not limited to analytical method validation, process optimization, {{party_name}} studies, preparation of quality risk assessments, preparation of validation protocols and report per stage, preparation of validation master protocol and report, preparation of process performance assessment) will be handled separately from the commercial unit pricing under separate {{party_name}} of Work or {{party_name}}s. Until otherwise agreed, all pricing for process qualification services to be similar to current framework between {{party_name}} and {{party_name}}. Article 6 {{party_name}}s 6.1 Placement of {{party_name}}s Consistent with the Short {{party_name}} Rolling Forecast as set forth in Section 4.1, {{party_name}} shall place with {{party_name}} {{party_name}}s, stating {{party_name}}’s required delivery data, anticipated delivery schedule and the anticipated {{party_name}}, in accordance with the Fee Schedule set out in Exhibit C, for each delivery of {{party_name}} to be made under this {{party_name}}. {{party_name}}s must have at least [* * *] of lead time before anticipated delivery to allow sufficient time for {{party_name}}’s planning, raw material purchases, production and release. Each {{party_name}} shall constitute a firm, binding order, upon {{party_name}}’s acceptance thereof in accordance with Section 6.2. 6.2 Acceptance of Orders {{party_name}} may reject any {{party_name}} placed by {{party_name}} that is not placed in accordance with this {{party_name}} by giving written notice (e-mail shall constitute written notice) to {{party_name}} within a reasonable time, not to exceed [* * *] after receipt of each {{party_name}}, setting out the reason for such rejection. In the event {{party_name}} does not respond within [* * *], such {{party_name}} shall be considered accepted by CONFIDENTIAL Page 20 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. {{party_name}}. In the event the ordered amount of {{party_name}} under the {{party_name}} differs more than [* * *] from the firm portion of the most recent Short {{party_name}} Rolling Forecast or more than [* * *] from the firm portion of the most recent Short {{party_name}} Rolling Forecast, {{party_name}} shall [* * *]. In the event the terms and conditions of this {{party_name}} conflict with the terms and conditions of the {{party_name}}, the terms and conditions of this {{party_name}} shall take precedence unless otherwise agreed upon by the Parties. 6.3 Delays If, after acceptance of a {{party_name}}, {{party_name}} is unable for any reason to supply quantities of the {{party_name}} in accordance with the {{party_name}}s placed by {{party_name}} under Section 6.1 on the timelines set forth therein, {{party_name}} shall inform {{party_name}} within [* * *] of becoming aware of its inability to supply the {{party_name}} of the expected duration of such inability and shall keep {{party_name}} informed on a timely basis of developments during any such period of time. The Parties shall cooperate to expedite the scheduling of the resumption of {{party_name}} of the {{party_name}} by {{party_name}} when any such inability has been alleviated. In the event of any delay in delivery of {{party_name}} from the delivery date on the applicable {{party_name}} for such {{party_name}}, if such delay is: [* * *]. 6.4 Cancellation of {{party_name}}s In the event that {{party_name}} cancels all or part of a {{party_name}} already accepted by {{party_name}}, {{party_name}} will use best efforts to reallocate capacity and mitigate any resultant costs of such cancellation. Except as expressly set forth in Section 3.4, Section 6.2, Section 6.3 and Section 6.5, the following will be charged to {{party_name}}: [* * *] 6.5 Material Failure of Supply If {{party_name}}, for any reason, fails to supply at least [* * *] of the units of {{party_name}} ordered by {{party_name}} pursuant to valid {{party_name}}s during any period of [* * *] or longer beginning on the requested delivery date, in addition to and without limiting any other remedies available to {{party_name}}, [* * *]. 6.6 {{party_name}} From time-to-time during the {{party_name}}, {{party_name}} may request that {{party_name}} perform {{party_name}} for {{party_name}} relating to the {{party_name}}, for which {{party_name}} shall pay reasonable compensation to {{party_name}}. In the event that {{party_name}} is willing to perform any such {{party_name}} requested by {{party_name}}, {{party_name}} will first prepare a scope of work describing the {{party_name}} to be performed and the costs to {{party_name}} for the approval of {{party_name}} (each CONFIDENTIAL Page 21 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. a “{{party_name}}”). No {{party_name}} shall be commenced by {{party_name}} unless (a) a {{party_name}} relating to such {{party_name}} has been agreed, executed and delivered by both {{party_name}} and {{party_name}}; and (b) a {{party_name}} has been issued by {{party_name}} and accepted by {{party_name}} relating to such {{party_name}} which {{party_name}} references the specific {{party_name}} and this {{party_name}}. {{party_name}} shall have the right to terminate any {{party_name}} and corresponding {{party_name}} for {{party_name}} at any time on reasonable advance written notice to {{party_name}} (without terminating this {{party_name}}), in which case {{party_name}} shall be responsible for: [* * *] Article 7 Shipment of {{party_name}} 7.1 Storage of {{party_name}} {{party_name}} shall ensure that all {{party_name}} held in storage is stored in accordance with {{party_name}} until shipped to {{party_name}} under this {{party_name}} and that all storage areas meet cGMP {{party_name}}. [* * *] Should any {{party_name}}, during storage, change chemical composition, then {{party_name}} and {{party_name}} will agree upon a plan for disposition of the {{party_name}}, including possible disposal, reworking or using the {{party_name}} “as is.” For clarity, {{party_name}} shall not commence any action set forth in the preceding sentence until such a plan has been agreed by {{party_name}}. The cost of reworking the {{party_name}} shall be borne by [* * *]. The cost of storage, monitoring (including any on-going analytical analysis), and insurance before shipment shall be borne by [* * *]. 7.2 {{party_name}} a) {{party_name}} shall notify {{party_name}} by facsimile or electronic transmission of each batch of {{party_name}} {{party_name}}d by it under this {{party_name}} in accordance with this Article 7 as soon as reasonably possible, and no later than [* * *], after {{party_name}}’s quality assurance department approves the batch for release following successful completion of the release testing procedures. b) {{party_name}} shall pack and label shipping boxes and ship all orders of {{party_name}} in a prompt and timely manner and in accordance with international transport guidelines and regulations, {{party_name}}, and {{party_name}}’s reasonable written instructions including, as applicable, for such shipment and the terms of this {{party_name}}. c) {{party_name}} shall not sell or otherwise dispose of any {{party_name}} except in accordance with the terms and conditions of this {{party_name}}. d) The {{party_name}}s will be shipped [* * *]. All freight, applicable taxes (excluding any and all income taxes, employment taxes and the like incurred by {{party_name}}), duties, express and delivery charges shall be for CONFIDENTIAL Page 22 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. {{party_name}}’s account and shall not be subject to discount. Delivery shall be deemed completed and risk of loss or damage of the {{party_name}}s shall pass to {{party_name}} upon [* * *]. Title to the {{party_name}}s shall pass to {{party_name}} upon [* * *]. 7.3 Documentation {{party_name}} shall include with each shipment of {{party_name}} shipped to {{party_name}} under Section 7.2: a) commercially appropriate documentation; b) a {{party_name}} and Certificate of Compliance in English for each batch of {{party_name}} included in the shipment, in the forms set out in Exhibit D; and c) a copy of any deviation or investigation reports concerning each batch of {{party_name}} shipped (to be sent separately from shipment as part of the batch record documentation). 7.4 {{party_name}} The Parties agree to form a steering committee (the “{{party_name}}”) to oversee their interactions under this {{party_name}} as provided herein. Each {{party_name}} shall name a mutually agreed upon equal number of representatives to the {{party_name}}, which shall meet either in person or remotely (as mutually agreed) at least [* * *], or as otherwise mutually agreed by the Parties. The primary function of the {{party_name}} is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this {{party_name}}. The {{party_name}} shall in particular have responsibility for the following: (a) reviewing key metrics for the {{party_name}}’s production and quality, and reviewing and monitoring any required remediation with respect to production and quality for the {{party_name}}; (b) reviewing {{party_name}}’s capacity and short-term and long-term planning for clinical and commercial supply of the {{party_name}}, including anticipating any capacity shortfalls and discussing the cost allocation of investments required to increase capacity or improve efficiencies; (c) [* * *]; (d) reviewing and discussing draft {{party_name}} of Work; (e) discussing the cost allocation, if any, of extraordinary costs incurred by {{party_name}} in connection with {{party_name}} or provision of {{party_name}}; and (f) establishing resource priorities and resolving resource conflicts. Article 8 Acceptance of Shipments 8.1 Acceptance of Shipments {{party_name}} or its designees shall, within a period of [* * *] after the date of physical receipt of any shipment of {{party_name}} from {{party_name}}, inspect the {{party_name}} for any shortages or any defects or deviations of {{party_name}} Page 23 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Specifications (hereinafter “Out Of Specification”) that would be apparent from visual inspections of the {{party_name}}. In the event that {{party_name}} is of the opinion that the {{party_name}} is Out Of Specification at the time of delivery, {{party_name}} shall, within [* * *] after the date of physical receipt of {{party_name}}, provide {{party_name}} with a written notice to reject the {{party_name}} (a “Notice of Rejection”), which shall include a description of the grounds for rejection and copies of test reports and testing methodology conducted on the {{party_name}}, if any. However, with respect to any Out Of Specification {{party_name}} which would not be apparent from a reasonable visual inspection on delivery, including in the case of any hidden defects, such Notice of Rejection shall be provided to {{party_name}} not later than [* * *]. The failure of {{party_name}} or its designees to notify {{party_name}} of any Out Of Specification {{party_name}} in the manner set forth herein above shall constitute confirmation of the acceptance thereof. 8.2 Dispute of Rejected {{party_name}} {{party_name}} may, at its option, within [* * *] of receipt of any Notice of Rejection under Section 8.1, challenge the Notice of Rejection by delivering written notice thereof to {{party_name}}. In the event that {{party_name}} challenges the Notice of Rejection, {{party_name}} and {{party_name}} shall conduct a joint investigation. If {{party_name}} and {{party_name}} are unable to resolve the issue of non-compliance then a sample of the {{party_name}} will be submitted to an independent laboratory reasonably acceptable to both Parties for testing against {{party_name}}, and determination whether or not the non-compliance may be caused by a fault on the part of {{party_name}}. The test results of the independent laboratory testing shall be final and binding upon {{party_name}} and {{party_name}}, and the fees and expense of such laboratory testing shall be borne entirely by the {{party_name}} against whom such laboratory’s findings are made. 8.3 Remedies a) Except as set forth in this {{party_name}}, in the event of a {{party_name}} shortage[* * *]. b) In the event that {{party_name}} issues a timely Notice of Rejection in respect to any Out Of Specification {{party_name}}: [* * *] The {{party_name}} in possession of any rejected {{party_name}} which does not comply with {{party_name}} or cGMP {{party_name}} shall destroy, in accordance with all {{party_name}} and in a manner to which {{party_name}} has given its prior written approval, all rejected {{party_name}} in its possession, but only after the Parties have followed the procedures specified under {{party_name}} and 8.3. No rejected {{party_name}} shall be sold, reprocessed, salvaged, reclaimed or otherwise reused in any manner by {{party_name}} or {{party_name}} without the prior written agreement of the Parties with the exception of use testing and analysis by {{party_name}} and/or {{party_name}} in the investigating the cause of {{party_name}} rejection. Representatives of the {{party_name}} not performing the destruction shall be permitted to witness the destruction of the rejected {{party_name}} under this section. CONFIDENTIAL Page 24 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Article 9 {{party_name}} a) {{party_name}} shall pay to {{party_name}}, in respect of each {{party_name}} placed by {{party_name}}, the applicable {{party_name}} for the supply of the {{party_name}} in bulk quantities under this {{party_name}}, in accordance with the terms of this {{party_name}}. b) Except as otherwise expressly provided in this {{party_name}}, the {{party_name}} specified in each {{party_name}} accepted by {{party_name}} shall be full compensation for all Manufacturing and characterization activities and Materials in respect thereof. {{party_name}} shall make all requests for processing changes to be performed under this {{party_name}} in writing under Section 3.5 and {{party_name}} shall provide {{party_name}} a cost estimate for such work. 9.2 Adjustments to {{party_name}} During the {{party_name}} of this {{party_name}}, either {{party_name}} may request an increase or decrease of the {{party_name}} specified in Exhibit C no more than [* * *] and such change in {{party_name}} shall take effect on [* * *] for which such Fee change is requested. Such change in {{party_name}} may be requested due to any of the following events: [* * *] or (iii) any other cost adjustments mutually agreed to by the Parties via the {{party_name}}. {{party_name}} will make available to {{party_name}} records that substantiate any adjustment to {{party_name}} for a {{party_name}} proposed by {{party_name}} and {{party_name}} will provide {{party_name}} with any {{party_name}} records that provide evidence for a decrease in {{party_name}} pursuant to clause (i); such records to be considered {{party_name}}‘s {{party_name}} hereunder. The {{party_name}} proposing an adjustment in the {{party_name}} will notify the other {{party_name}} of the adjustment by delivering to the other {{party_name}} at least [* * *] prior to the effective date of the {{party_name}} adjustment, written notice of the proposed adjustment. Said written notice shall specify the effective date as [* * *] in which the Fee adjustment becomes effective and the amounts for the adjusted {{party_name}}. On receipt of such request, the Parties shall seek in good faith to agree to an adjustment of the {{party_name}}, based on such reasonable and objective evidence. Each {{party_name}} shall use its commercially reasonable efforts to mitigate any cost increase. The {{party_name}} for any {{party_name}} ordered by {{party_name}} prior to the effective date of the {{party_name}} adjustment shall be the {{party_name}} existing on the date {{party_name}} placed the {{party_name}}, as set out in the {{party_name}}. CONFIDENTIAL Page 25 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. 9.3 {{party_name}} The {{party_name}} shall be exclusive of any taxes, customs duties, levies and other charges applicable to the supply of the {{party_name}} under this {{party_name}} (“{{party_name}}”). {{party_name}} shall pay any {{party_name}} and reimburse {{party_name}} for any {{party_name}} for which {{party_name}} is responsible but which have been paid by {{party_name}}. Subject to compliance with laws, the Parties shall reasonably cooperate to eliminate or minimize the amount of any such {{party_name}} imposed on the transactions contemplated in this {{party_name}}. For clarity, {{party_name}} shall not be liable for any taxes incurred by the {{party_name}} including, without limitation, income taxes, employment taxes, use taxes, and the like incurred by {{party_name}}, or for any penalties or interest related to the failure of {{party_name}} to collect sales, use, {{party_name}} or similar taxes. Article 10 Invoicing and Payment 10.1 Issuance of Invoices {{party_name}} shall, in accordance with Section 10.2, invoice {{party_name}} for each {{party_name}} accepted under Section 6.2 as follows: 10.2 Invoice Contents All invoices issued by {{party_name}} under Section 10.1 shall show: a) the actual quantity of {{party_name}} shipped; b) the lot number of each batch of {{party_name}} shipped; c) the {{party_name}} for the quantity of {{party_name}} shipped, based on the {{party_name}} for the {{party_name}} set out in the applicable {{party_name}}; and d) the {{party_name}} number placed by {{party_name}} for the {{party_name}} shipped. If {{party_name}} disputes for any reason with the amount of any invoice submitted by {{party_name}}, {{party_name}} shall notify {{party_name}} of such dispute within [* * *] after the date of the invoice, and the Parties shall promptly attempt to resolve the dispute. If {{party_name}} does not notify {{party_name}} of any such dispute within such [* * *] period, such invoice will be final and binding on {{party_name}} and {{party_name}}, subject to the correction of mathematical errors. CONFIDENTIAL Page 26 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. 10.3 Delay of Shipment If {{party_name}} delays shipment of {{party_name}} released by {{party_name}} in accordance with Section 7.2, {{party_name}} may issue its invoice under Section 10.1 on or after the release, with reference to the {{party_name}} released under Section 10.2. 10.4 Payment of Invoices Each invoice provided by {{party_name}} to {{party_name}} under Section 10.1, to the extent accurate, shall be paid by {{party_name}} to {{party_name}} within [* * *] after the date of the invoice to the extent that {{party_name}} does not reasonably dispute that portion of the invoice in good faith. All payments will be made in U.S. Dollars by SWIFT bank transfer directly to the {{party_name}} account as specified in the respective {{party_name}}s. Article 11 {{party_name}} 11.1 Title a) The Parties agree that, as between {{party_name}} and {{party_name}}, each {{party_name}} owns its respective {{party_name}}, {{party_name}} owns all Rights in and to the {{party_name}} Technology, the {{party_name}}(s) and its {{party_name}} and {{party_name}} owns all Rights in and to {{party_name}} Technology. b) {{party_name}} shall not knowingly use in the Manufacturing Process any {{party_name}} protected by any patent or patent application licensed to {{party_name}} by any Third {{party_name}}, except with the prior written consent of {{party_name}}. 11.2 No Grant of Rights Except as otherwise provided herein, neither {{party_name}} hereto shall be deemed by this {{party_name}} to have been granted any Rights of the other {{party_name}}. CONFIDENTIAL Page 27 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. WHERE TWO P{{party_name}}ES OF MATERIAL HAVE BEEN OMITTED, THE REDACTED MATERIAL IS MARKED WITH [†]. 11.3 {{party_name}} by {{party_name}} During the {{party_name}}, {{party_name}} hereby grants to {{party_name}} a paid-up, royalty-free, non-exclusive license, without the right to sublicense, to {{party_name}}’s {{party_name}} and the {{party_name}} Technology reasonably necessary to {{party_name}} and supply to {{party_name}} the {{party_name}} hereunder, but only for such purposes. The Parties agree that the license grant contained in this Section 11.3 is personal to {{party_name}} only and shall be exercised by {{party_name}} only, and {{party_name}} agrees to make use of {{party_name}}’s {{party_name}} and the {{party_name}} Technology only in accordance with this license and not to disclose any such {{party_name}} or {{party_name}} Technology to any Third {{party_name}}, except that nothing herein shall prevent {{party_name}} from disclosing to its permitted subcontractors under confidentiality obligations at least as strict as those that bind {{party_name}} under this {{party_name}}, as necessary to perform {{party_name}}’s obligations hereunder. 11.4 Ownership of Inventions With respect to any ideas, innovations, Improvements or inventions (whether patentable or non-patentable) developed by {{party_name}} during the {{party_name}} of this {{party_name}} and [* * *], the Parties agree that, as between {{party_name}} and {{party_name}}, {{party_name}} shall own all Rights to such Inventions and may obtain patent, copyright, and other proprietary protection respecting such Inventions. {{party_name}} agrees to promptly disclose any Inventions to {{party_name}}. {{party_name}} agrees to assign (and cause its employees or permitted subcontractors to assign), and does hereby assign, any and all rights, title and interests of {{party_name}} in, to or under any Inventions to {{party_name}}. [* * *] 11.5 Patents to Inventions With respect to all {{party_name}} created or developed under this {{party_name}}, [* * *]. 11.6 No Use of Trademarks Nothing contained herein shall give either {{party_name}} any right to use any trademark of the other {{party_name}}. All trademarks and service marks adopted by {{party_name}} to identify the {{party_name}} or a {{party_name}} {{party_name}} are and shall remain the property of {{party_name}}. 11.7 [†] CONFIDENTIAL Page 28 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Article 12 {{party_name}} 12.1 Obligation of Confidentiality It is contemplated that in the course of the performance of this {{party_name}} each {{party_name}} may, from time to time, disclose {{party_name}} to the other. Each {{party_name}} agrees: a) to keep and use in strict confidence all {{party_name}} of the other {{party_name}} that each {{party_name}} acquires, sees, or is informed of, as a direct or indirect consequence of this {{party_name}} and to not, without the prior written consent of the other {{party_name}}, disclose any such {{party_name}} or recollections thereof to any person or entity other than its corporate counsel, employees and contractors who are under an obligation of confidentiality on terms substantially similar to those set out in this {{party_name}}, who have been informed of the confidential nature of the {{party_name}} and who reasonably require such information in the performance of their duties under this {{party_name}}; b) not to use, copy, duplicate, reproduce, translate or adapt, either directly or indirectly, any of the {{party_name}} of the other {{party_name}} or any recollections thereof for any purpose other than the performance of the {{party_name}} and the {{party_name}} and characterization of the {{party_name}} under this {{party_name}}, without the other {{party_name}}’s prior written approval; c) that all copies, duplicates, reproductions, translations or adaptations of any {{party_name}} of the other {{party_name}} permitted to be made hereunder shall be clearly labelled as {{party_name}} and d) to take all reasonable steps to prevent material in its possession that contains or refers to {{party_name}} of the other {{party_name}} from being discovered, used or copied by Third Parties and to use reasonable steps to protect and safeguard all {{party_name}} of the other {{party_name}} in its possession from all loss, theft or destruction. Upon the termination of this {{party_name}}, each {{party_name}} shall promptly destroy or return all {{party_name}} to the disclosing {{party_name}} in accordance with Section 18.4. 12.2 Disclosure with Consent A {{party_name}} receiving {{party_name}} may, with the written consent of the disclosing {{party_name}}, disclose such {{party_name}} to entities or persons other than its corporate counsel, employees and contractors, on such terms and conditions as the disclosing {{party_name}} may specify. 12.3 Publicity During the {{party_name}}, the Parties agree that no press release, public announcement or publication regarding this {{party_name}} or the relationship of the Parties (except to the extent that it may be legally required), shall be made unless mutually agreed to in writing prior to the release or dissemination of any such press release, public announcement or publication. CONFIDENTIAL Page 29 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. 12.4 Disclosure Required by Law No provision of this {{party_name}} shall be construed so as to preclude such disclosure of {{party_name}} of the other {{party_name}} as may be inherent in or reasonably necessary to the securing from any governmental agency of any necessary regulatory approval or license. To the extent required by legal process, subpoena, warrant, or court order, either {{party_name}} may disclose {{party_name}} only to the extent required to comply with said legal proceeding, provided that the {{party_name}} obligated to make such disclosure shall, when lawfully permissible, provide reasonable prior notice the other {{party_name}} so as to allow the other {{party_name}} to take steps to oppose or limit the required disclosure. 12.5 {{party_name}}. (a) {{party_name}} acknowledges and agrees that, with respect to any past or current employee, staff, contractor, subcontractor or other agent of {{party_name}} or its {{party_name}} who has conducted services or activities related to the development, manufacture or supply of {{party_name}}s for or to {{party_name}} (collectively, the “{{party_name}} Employees”), {{party_name}} or its {{party_name}} has entered into a binding written arrangement(s) with each such {{party_name}} Employee that requires: (i) that such {{party_name}} Employee will, at a minimum, keep the {{party_name}} of {{party_name}} confidential and only use such {{party_name}} to conduct permitted activities for {{party_name}} under {{party_name}}’s employment; and (ii) that such {{party_name}} Employee assign to {{party_name}} all of its right, title and interest in and to any inventions (including, without limitation, know-how, improvements, ideas, information, materials and processes) and all intellectual property rights therein that such {{party_name}} Employee, alone or jointly with others, conceives, develops or reduces to practice during their period of employment or work with {{party_name}} or its {{party_name}}. (b) {{party_name}} further covenants and agrees that, (i) with respect to any future {{party_name}} Employee, {{party_name}} or its {{party_name}} shall enter into a binding written arrangement with such {{party_name}} Employee as set forth in {{effective_date}}) and (ii) with respect to any binding written arrangement referred to in this Section 12.5(b) or {{effective_date}}), {{party_name}} shall enforce, to the fullest extent permitted under {{party_name}}, the terms and provisions of such arrangement. 12.6 {{party_name}} otherwise agreed by the Parties in writing, the obligations of the Parties relating to {{party_name}} set out in this Article 12 shall survive the termination of this {{party_name}} for a period of [* * *]. CONFIDENTIAL Page 30 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Article 13 Representations, {{party_name}} and Covenants 13.1 {{party_name}}’s Representations, {{party_name}} and Covenants {{party_name}} hereby represents, warrants and covenants to {{party_name}} as follows: a) {{party_name}} has been duly organized and is validly subsisting and in good standing in its jurisdiction of organization and has the power to carry on the business as now being conducted by it; b) the execution, delivery and performance of this {{party_name}} by {{party_name}} have been duly authorized by all requisite corporate action and do not require any shareholder action or approval; c) {{party_name}} has the right and authority to enter into this {{party_name}} and perform its obligations hereunder, and this {{party_name}} is a legal and valid obligation binding upon {{party_name}} and enforceable in accordance with its terms; d) {{party_name}} has not made and will not make any commitments to Third Parties inconsistent with or in derogation of {{party_name}}’s obligations under this {{party_name}} and {{party_name}} is to its knowledge not subject to any obligations that would prevent it from entering into or carrying out its obligations under this {{party_name}}, and {{party_name}}’s compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financing agreement, agreement affecting a {{party_name}} or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its charter or operative documents or by-laws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; e) {{party_name}} shall comply with all {{party_name}} relating to its activities under this {{party_name}}; f) all {{party_name}} delivered to {{party_name}} under this {{party_name}} will have been {{party_name}}d, stored and shipped in a competent fashion in accordance with {{party_name}} {{party_name}}, {{party_name}}, this {{party_name}}, the Quality {{party_name}}, {{party_name}} and cGMP {{party_name}} by qualified personnel and, to {{party_name}}’s knowledge, will be free from defects; g) the {{party_name}}, including equipment, systems, utilities and services, complies with cGMP {{party_name}} for the {{party_name}} of the {{party_name}} under {{party_name}}) the {{party_name}} and {{party_name}}’s procedures and processes in the {{party_name}} are in compliance with {{party_name}}, including applicable environmental, health and safety requirements, for the {{party_name}} of the {{party_name}} under this {{party_name}}; i) {{party_name}} does not, at any time from and after {{party_name}}, retain or use the services of (i) any person debarred under 21 U.S.C. § 335a or (ii) any person who has been convicted of a crime as defined under the FD&C Act, in each case in any capacity associated with or related to the {{party_name}} or supply of {{party_name}}s or any service rendered to {{party_name}} under this {{party_name}} or the Quality {{party_name}}; j) all {{party_name}} supplied by {{party_name}} under this {{party_name}} shall be delivered by it free and clear of any security interests, liens, claims, pledges or encumbrances of any kind or nature except for such as are created by {{party_name}}; and k) all records and reports required to be maintained by {{party_name}} under cGMP {{party_name}} shall be accurate and complete in all material respects. CONFIDENTIAL Page 31 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. In no event shall {{party_name}} seek to recover a refund for, or replacement to, an Out of Specification {{party_name}} due to {{party_name}}’s breach of {{party_name}} (f), (g) or (h) except pursuant to Article 8. 13.2 {{party_name}}’s Representations, {{party_name}} and Covenants {{party_name}} hereby represents, warrants and covenants to {{party_name}} as follows: a) {{party_name}} has been duly organized and is validly subsisting and in good standing in its jurisdiction of organization and has the power to carry on the business as now being conducted by it; b) the execution, delivery and performance of this {{party_name}} by {{party_name}} have been duly authorized by all requisite corporate action and do not require any shareholder action or approval; c) {{party_name}} has the right and authority to enter into this {{party_name}} and perform its obligations hereunder, and this {{party_name}} is a legal and valid obligation binding upon {{party_name}} and enforceable in accordance with its terms; d) {{party_name}} has not made and will not make any commitments to Third Parties inconsistent with or in derogation of {{party_name}}’s obligations under this {{party_name}} and {{party_name}} is not subject to any obligations that would prevent it from entering into or carrying out its obligations under this {{party_name}}, and {{party_name}}’s compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financing agreement, agreement affecting a {{party_name}} or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its charter or operative documents or by-laws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; e) {{party_name}} shall comply with all {{party_name}} relating to its activities under this {{party_name}}; and f) to {{party_name}}’s knowledge, [* * *]. 13.3 No Other Warranty THE WARRANTIES SET OUT IN SECTIONS 13.1 AND 13.2 ARE THE SOLE WARRANTIES MADE BY EITHER {{party_name}}TY TO THE OTHER AND TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE {{party_name}}TIES HEREBY DISCLAIM ANY AND ALL OTHER WARRANTIES, REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, {{party_name}} OR IMPLIED, REGARDING THE PRODUCT OR ANY OTHER MATERIALS OR SERVICES TO BE SUPPLIED UNDER THIS {{party_name}}REEMENT, INCLUDING, BUT NOT LIMITED TO ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A {{party_name}}TICULAR PURPOSE. CONFIDENTIAL Page 32 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. 13.4 No {{party_name}} and Limitation of Liability a) [* * *], IN NO EVENT SHALL EITHER {{party_name}}TY BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, {{party_name}}, INCIDENTAL OR INDIRECT DAM{{party_name}}ES, OR LOST PROFITS, HOWEVER CAUSED, ON ANY THEORY OF {{party_name}}. THIS LIMITATION WILL APPLY EVEN IF THE OTHER {{party_name}}TY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAM{{party_name}}E. b) EXCEPT AS SET FORTH BELOW IN THIS SECTION 13.4(b), IN NO EVENT WILL SUPPLIER’S {{party_name}}, [* * *], BE GREATER THAN, PER CLAIM OR SERIES OF CLAIMS ARISING FROM THE SAME CAUSE OF ACTION, [* * *]. EXCEPT AS SET FORTH BELOW IN THIS SECTION 13.4(b), [* * *], AS APPLICABLE, IN NO EVENT SHALL A {{party_name}}TY’S {{party_name}}, HOWEVER CAUSED AND ON ANY THEORY OF {{party_name}}, BE GREATER THAN, PER CLAIM OR SERIES OF CLAIMS ARISING FROM THE SAME CAUSE OF ACTION, [* * *]. EXCEPT AS SET FORTH BELOW IN THIS SECTION 13.4(b), WITH {{party_name}} [* * *], IN NO EVENT SHALL A {{party_name}}TY’S {{party_name}} BE GREATER THAN, PER CLAIM OR SERIES OF CLAIMS ARISING FROM THE SAME CAUSE OF ACTION, [* * *]. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS SECTION 13.4(b), WITH {{party_name}} TO [* * *] IN NO EVENT SHALL SUPPLIER’S {{party_name}}, HOWEVER CAUSED AND ON ANY THEORY OF {{party_name}}, BE GREATER THAN, PER CLAIM OR SERIES OF CLAIMS ARISING FROM THE SAME CAUSE OF ACTION, [* * *]. [* * *] Article 14 Indemnification 14.1 Indemnification of {{party_name}} {{party_name}} shall indemnify, defend and hold harmless {{party_name}} and its officers, directors, agents, servants and employees against any and all actions, claims, demands, proceedings, suits, losses, damages, costs and expenses (including reasonable legal fees) of Third Parties (in this Article 14, “Claims”) (including Claims for personal injury or death) to the extent such Claims result from or arise out of (a) any product liability claim directly related to {{party_name}}’s commercial use, sale or distribution of {{party_name}}s or (b) {{party_name}}’s [* * *] acts or omissions or [* * *], except, in each case of clause (a) and (b), to the extent {{party_name}} has an obligation to indemnify {{party_name}} pursuant to Section 14.2 or 14.3. 14.2 Indemnification of {{party_name}} {{party_name}} shall indemnify, defend and hold harmless {{party_name}} and its {{party_name}} and {{party_name}} Licensees, and their respective officers, directors, agents, servants, employees and consultants against any and all Claims (including Claims for personal injury or death) to the extent such Claims result from or arise out of (a) any [* * *] acts or omissions or [* * *] by {{party_name}} or its officers, directors, agents, servants, CONFIDENTIAL Page 33 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. employees or contractors (collectively, the “{{party_name}} Representatives”) [* * *] or (b) any [* * *] or omissions or [* * *] by {{party_name}} or the {{party_name}} Representatives, except, in each case of clause (a) and (b), to the extent {{party_name}} has an obligation to indemnify {{party_name}} pursuant to Sections 14.1 or 14.3. 14.3 {{party_name}} Indemnity {{party_name}} (an “{{party_name}}”) shall indemnify, defend and hold harmless {{party_name}} and the {{party_name}} Representatives (each, an “Indemnified {{party_name}}”) from any and all Claims of any Third {{party_name}} that any {{party_name}} (including, without limitation, {{party_name}} Materials, {{party_name}} Information, {{party_name}} Specifications, {{party_name}} Technology or {{party_name}}), provided by {{party_name}} to {{party_name}} hereunder, infringes a Third {{party_name}}’s {{party_name}} Rights or otherwise violates a Third {{party_name}}’s rights. {{party_name}} (an “{{party_name}}”) indemnifies {{party_name}} and its {{party_name}} and {{party_name}} Licensees, and their respective officers, directors, agents, servants, employees and consultants (each, an “Indemnified {{party_name}}”) from any and all Claims of any Third {{party_name}} that the {{party_name}} (other than the {{party_name}} {{party_name}} has provided to {{party_name}} under this {{party_name}}) that {{party_name}} elects to use in conducting the activities set out in this {{party_name}}, infringes such Third {{party_name}}’s {{party_name}} Rights or otherwise violates a Third {{party_name}}’s rights. The {{party_name}}’s obligation to indemnify the Indemnified {{party_name}} shall apply only upon the following terms and conditions: a) the obligation shall only pertain to the {{party_name}} the {{party_name}}, its {{party_name}}, officers, directors, agents, servants, employees or consultants elect to use in conducting the activities set out in this {{party_name}}, and not to any Improvements or additions made by anyone other than the {{party_name}}, whether with or without permission; and b) [* * *] 14.4 Indemnification Procedure The indemnities contained in this Article 14 shall be conditional on compliance with the terms and conditions set out in this Section 14.4. The indemnifying {{party_name}} shall have the option to defend, contest, or otherwise protect against any such Claims at its own cost and expense provided that the party seeking indemnification (the “{{party_name}}”) regarding any such Claims gives written notice to the indemnifying {{party_name}} promptly after receiving notice of said Claims. If the indemnifying {{party_name}} chooses to defend Claims, the {{party_name}} may, but will not be obligated to, participate at its own expense in a defense thereof by counsel of its own choosing, but the indemnifying {{party_name}} shall be entitled to control the defense unless the {{party_name}} has relieved the indemnifying {{party_name}} from liability with respect to the particular matter. If the indemnifying {{party_name}} fails to timely defend, contest, or otherwise protect against any such Claims, the {{party_name}} may defend, contest, or otherwise protect against the same, and make any reasonable compromise or settlement thereof and recover the entire costs thereof from the indemnifying {{party_name}}, including reasonable legal fees and costs and disbursements, and all amounts paid as a result of such CONFIDENTIAL Page 34 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Claims or the compromise or settlement thereof; provided, however, that if the indemnifying {{party_name}} undertakes the timely defense of such matter, the {{party_name}} shall not be entitled to recover from the indemnifying {{party_name}} for its costs incurred in the defense thereof. The {{party_name}} shall cooperate and provide such assistance as the indemnifying {{party_name}} may reasonably request in connection with the defense of the matter subject to indemnification. Article 15 Insurance 15.1 Insurance Coverage {{party_name}} and {{party_name}} each represent that they are sufficiently insured against any liability arising under this {{party_name}}. Further, {{party_name}} shall at a minimum retain [* * *]. 15.2 Evidence of Insurance Each of {{party_name}} and {{party_name}} shall, upon request by the other, provide the other {{party_name}} with a copy of all insurance policies maintained under this Article 15 relating to the {{party_name}} of the {{party_name}} in bulk quantities and the facilities therefor and shall notify the other {{party_name}} in writing {{effective_date}} prior to the cancellation of or any material change to such insurance policies. Each {{party_name}} may request that the other {{party_name}} procure and maintain such additional insurance coverage relating to the {{party_name}} of the {{party_name}} and the facilities therefore as may be reasonably necessary in respect of the Parties’ respective obligations under this {{party_name}}. Article 16 Legal and Regulatory 16.1 Compliance with Laws a) Each {{party_name}} shall, in connection with its obligations, rights and duties under this {{party_name}} and in Manufacturing, handling, storage, loading, shipping, using, commercializing, reselling and distributing the {{party_name}}: (i) comply with all {{party_name}} or other requirements applicable to such {{party_name}}’s business; and (ii) subject to Subsection b) below, obtain and maintain in full force and effect all applicable licenses, permits, certificates, authorizations or approvals from local governmental authorities necessary to conduct its business and the activities contemplated under this {{party_name}}. Such licences or certificates are to be provided to the other {{party_name}} on request. b) {{party_name}} shall be responsible for obtaining all necessary import and/or export licenses or permits and for the payment of all import and/or export fees, taxes or duties in connection with the purchase and/or delivery of the {{party_name}} under this {{party_name}}. {{party_name}} shall reasonably cooperate with {{party_name}} in connection with obtaining necessary import and/or export licenses or permits. CONFIDENTIAL Page 35 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. 16.2 Maintenance of Records {{party_name}} shall maintain adequate books and records and retention samples consistent with cGMP {{party_name}} and any other {{party_name}} and requirements of applicable governmental or regulatory authorities, in respect of test records, samples and associated support data for all batches of {{party_name}} {{party_name}}d by {{party_name}} sufficient to substantiate and verify {{party_name}}’s duties and obligations under this {{party_name}} for [* * *] from the expiration date of the respective {{party_name}} batch. 16.3 Notice of Reports {{party_name}} shall provide to {{party_name}} within [* * *] of receipt by {{party_name}} copies of all {{party_name}}-specific portions of any reports of any governmental or regulatory authority including, without limitation, any {{party_name}}-specific reports solely to the extent applicable to the {{party_name}} or Manufacturing Process, {{party_name}} Form 483 observations, {{party_name}} warning letters or other correspondence from the {{party_name}} or equivalent correspondence from another {{party_name}}; provided that {{party_name}} may redact any information from such reports subject to confidentiality obligations and not related to the {{party_name}}. 16.4 {{party_name}} Master {{party_name}} {{party_name}} will routinely update and keep current all information pertinent to maintain the {{party_name}} Master {{party_name}} relating to the {{party_name}} of the {{party_name}} at the production site of {{party_name}}. {{party_name}} will fully support and reasonably assist {{party_name}} with its filing of any application with respect to the {{party_name}} with any {{party_name}} at {{party_name}}’s expense. 16.5 Compliance with Regulatory Standards {{party_name}} shall be responsible for Manufacturing the {{party_name}} in compliance with {{party_name}}, cGMP {{party_name}} and the standards of any other applicable governmental or regulatory authority. Each {{party_name}} will provide reasonable assistance to the other, at no charge, if necessary to respond to audits, inspections, inquiries, or requests of any {{party_name}}. {{party_name}} shall advise {{party_name}} immediately if {{party_name}} receives notice of an impending inspection related to a {{party_name}} or if an authorized agent of any {{party_name}} or other governmental agency provides advance notice of any investigation, inspection or visit to a {{party_name}}. In such event, {{party_name}} shall permit, to the extent permitted by {{party_name}}, {{party_name}} or its representatives to be present during such visit, at {{party_name}}’s expense. Upon {{party_name}}’s request, {{party_name}} shall provide {{party_name}} with a copy of any report issued by {{party_name}} following such visit. 16.6 Inspection {{party_name}} shall allow monitoring of the {{party_name}} as set forth in Section 3.6 and inspections or audits as provided for in the Quality {{party_name}}. {{party_name}} shall make available to {{party_name}} all relevant records and reports and {{party_name}} shall have the right to copy all {{party_name}} related records and reports. The frequency of such audits as well as the response time with respect to audit findings shall be governed by the Quality {{party_name}}. CONFIDENTIAL Page 36 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Article 17 {{party_name}}s 17.1 Safety {{party_name}} shall provide {{party_name}} with reasonable co-operation to help {{party_name}} investigate adverse events or product complaints involving or related to the {{party_name}}. The cost and expense of any testing undertaken by {{party_name}} at {{party_name}}’s request shall be borne by [* * *]. 17.2 {{party_name}}s If either {{party_name}} has grounds to recommend a {{party_name}} or otherwise receives a notification or information which might result in a {{party_name}}, the {{party_name}} recommending such {{party_name}} or receiving such notification or information shall immediately notify the other {{party_name}} in writing. Subject to {{party_name}}, {{party_name}} and its designees shall have the sole responsibility to implement any {{party_name}} of the {{party_name}} or any intermediate or finished product containing the {{party_name}} and the sole right to make all final decisions regarding any such {{party_name}}. {{party_name}} shall reasonably cooperate with {{party_name}} and its designees in implementing any such {{party_name}}, at {{party_name}}’s expense. 17.3 {{party_name}}’s Liability for {{party_name}} In the event of a {{party_name}} or Seizure arising from [* * *], {{party_name}} shall be liable for the expenses and out-of-pocket costs actually incurred by {{party_name}} as a result of such {{party_name}} or Seizure, and {{party_name}} shall, at the option of {{party_name}}: [* * *]. Such liability shall not limit or otherwise be exclusive of any other provisions of this {{party_name}}. 17.4 {{party_name}}’s Liability for {{party_name}} In the event of a {{party_name}} or Seizure arising from [* * *] {{party_name}} shall [* * *]. Such liability shall not be exclusive of any other provisions of this {{party_name}}. 17.5 Replacement Shipments In the event of any {{party_name}} or Seizure with respect to the {{party_name}} during the {{party_name}} of this agreement, {{party_name}} shall, upon the written request of {{party_name}}, as soon as reasonably possible, supply replacement {{party_name}} to {{party_name}} in an amount sufficient to replace the amount of {{party_name}} {{party_name}}ed or Seized, at the applicable then current {{party_name}} for {{party_name}} under this {{party_name}}. If {{party_name}} makes such written request, {{party_name}} shall issue a {{party_name}} in this regard which {{party_name}} is obliged to accept. {{party_name}} agrees to use commercially reasonable efforts to supply such replacement {{party_name}} pursuant to the new {{party_name}} as soon as possible. CONFIDENTIAL Page 37 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Article 18 {{party_name}}ination 18.1 {{party_name}}ination This {{party_name}} is effective as of {{party_name}} and will expire in accordance with Section 2.1, unless, upon the occurrence of any of the following events, this {{party_name}} is earlier terminated in accordance with this Section 18.1: a) {{party_name}} delivers written notice of termination to {{party_name}} at least [* * *] prior to the expiration date of the Initial {{party_name}}, which termination shall be effective as of the expiration date of the Initial {{party_name}}; b) either {{party_name}} delivers written notice of termination to the other {{party_name}} at least [* * *] prior to the expiration date of the Renewal {{party_name}}, which termination shall be effective as of the expiration date of the Renewal {{party_name}}; c) a {{party_name}} makes a general assignment for the benefit of creditors, a court of competent jurisdiction declares a {{party_name}} insolvent or bankrupt, or a petition in bankruptcy or under any insolvency law is filed by or against a {{party_name}} and such petition is not dismissed within [* * *] after it has been filed, and the other {{party_name}} delivers written notice of termination to such {{party_name}}, which termination shall be effective immediately upon delivery of such written notice; d) a {{party_name}} breaches a material provision of this {{party_name}}, and the other {{party_name}} delivers written notice of termination to such breaching {{party_name}}: (i) if the breach is not cured within [* * *] after written notice thereof to the {{party_name}} in default; or (ii) if the breach is of a type that cannot be cured within [* * *], if a cure is not promptly commenced and diligently pursued until complete remediation but in any case after [* * *] unless otherwise agreed in writing between the Parties; e) any governmental law, regulation or order is adopted and made effective which would make performance of a {{party_name}}’s obligations under this {{party_name}} impossible or commercially impracticable, and such {{party_name}} delivers written notice of termination to the other {{party_name}}, which termination shall be effective immediately upon delivery of such written notice; or f) a {{party_name}} has the right to terminate under Section 14.3, which termination shall be effective [* * *] after delivery of written notice to the non- terminating {{party_name}}. CONFIDENTIAL Page 38 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. 18.2 Consequences of {{party_name}}ination On expiration or the effective date of termination of this {{party_name}}, if earlier: a) both Parties shall be released from all obligations and duties imposed or assumed hereunder, except obligations and liabilities previously accrued and as expressly provided by this {{party_name}}, including, without limitation, those provisions which expressly survive termination or expiration of this {{party_name}}; b) all Rights granted by {{party_name}} to {{party_name}} under Section 11.3 shall immediately revert to {{party_name}}, provided that {{party_name}} may continue to use any such Rights in order to fulfil its surviving obligations under Section 18.5, and only for such purpose; c) {{party_name}} shall provide to {{party_name}}, to the extent they exist, copies of: (i) {{party_name}}’s Manufacturing batch records and analytical reports relating to the {{party_name}}; and (ii) any other documents required to be delivered pursuant to this {{party_name}} or otherwise reasonably requested by {{party_name}}; d) Unless this {{party_name}} is terminated by {{party_name}} pursuant to Section 18.1(d) above, all {{party_name}}s and {{party_name}} of Work shall automatically be deemed terminated by {{party_name}} and {{party_name}} shall be compensated for final {{party_name}} already produced or {{party_name}} already rendered in accordance with this {{party_name}} and, for {{party_name}}s or {{party_name}} not yet produced or rendered, as the case may be, {{party_name}} shall be entitled to its fees, expenses and costs as set forth in {{party_name}} and 6.6. Additionally, {{party_name}} shall be entitled to request that (i) all {{party_name}}s and/or works in process for which {{party_name}} has compensated {{party_name}} and (ii) all {{party_name}} Materials be shipped to {{party_name}} in accordance with the provisions of Section 7.2(d). If this {{party_name}} is terminated by {{party_name}} pursuant to Section 18.1(d) as a result of {{party_name}}’s breach, then, {{party_name}} shall be able to elect whether {{party_name}}s or {{party_name}} of Work not yet completed at the date of termination or expiration should continue in force, subject to the terms and conditions herein; and e) {{party_name}} shall promptly cooperate with {{party_name}} to transfer and transition supply of the {{party_name}}s to a Third {{party_name}} supplier. Upon {{party_name}}’s request, {{party_name}} shall cooperate with {{party_name}} in the transfer of technology and know-how necessary to {{party_name}} {{party_name}}s to such Third {{party_name}} supplier, including providing {{party_name}} and the Third {{party_name}} supplier with reasonable access to the {{party_name}} and consulting services related to Manufacturing of the {{party_name}}. {{party_name}} shall conduct such activities at {{party_name}}’s expense paid in advance. CONFIDENTIAL Page 39 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. {{amount}} of Samples On expiration or earlier termination of this {{party_name}}, unless otherwise instructed by {{party_name}}, {{party_name}} shall, within [* * *], return to {{party_name}} all samples or other supplies of the {{party_name}} (for which {{party_name}} has been paid) in its possession or control in any form, with the exception of any samples such as retention samples that {{party_name}} may be required to keep according to {{party_name}}. The cost of returning any such supplies shall: [* * *] 18.4 Return of {{party_name}} On expiration or earlier termination of this {{party_name}}, unless otherwise agreed between the Parties, each {{party_name}} shall: a) promptly cease all use of the {{party_name}} of the other {{party_name}} and ensure that its corporate counsel, employees and contractors cease all use thereof; and b) upon written request of the other {{party_name}}, (i) return to the other {{party_name}} all original copies of the {{party_name}} of the other {{party_name}} in its control or possession, subject to the retention of one (1) complete copy for archival purposes and to satisfy any applicable legal requirements; and (ii) except for back-up copies generated by the recipient {{party_name}}’s IT system, destroy any and all copies or other reproductions or extracts of the {{party_name}} of the other {{party_name}} and all other documents, computer files, memoranda, notes or other writings prepared based on such {{party_name}} subject to clause (i) above. 18.5 Survival Except as otherwise provided herein or agreed in writing between the Parties, expiration or early termination of this {{party_name}} shall not relieve either {{party_name}} of its obligations incurred prior to such expiration or early termination, including the obligation to {{party_name}} and deliver the {{party_name}} under {{party_name}}s placed by {{party_name}} and accepted by {{party_name}} prior to the effective date of expiration or earlier termination, and the obligation to pay {{party_name}} in respect thereof. In addition, the following provisions shall survive any expiration or early termination of this {{party_name}} in accordance with the terms of such provision; provided that if there is no express expiration or termination of an obligation or a right under a surviving provision, such provision or right shall continue to survive, subject to {{party_name}}[* * *]: Article 1 (Interpretation); Section 2.2 (Effect of Expiration on {{party_name}}s); Section 5.3 (Retention Samples); Article 9 ({{party_name}}) (solely with respect to amounts owed or paid following {{party_name}} Article 11 ({{party_name}}) (other than Section 11.3 ({{party_name}} by {{party_name}})); Article 12 ({{party_name}}); Section 13.3 (No other Warranty); Section 13.4 (No {{party_name}} and Limitation of Liability); Article 14 (Indemnification); Article 15 (Insurance); Section 16.2 (Maintenance of Records); Section 16.4 ({{party_name}} Master {{party_name}}); Section 16.6 (Inspection); Sections 17.2 CONFIDENTIAL Page 40 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. ({{party_name}}s), 17.3 ({{party_name}}’s Liability for {{party_name}}) and 17.4 ({{party_name}}’s Liability for {{party_name}}); Sections 18.2 (Consequences of {{party_name}}ination), 18.3 (Return of Samples) and 18.4 (Return of {{party_name}}); this Section 18.5 (Survival); and Article 19 (Miscellaneous) (except {{effective_date}} and 19.5). Further, Article 8 (Acceptance of Shipments) shall survive any expiration or termination of this {{party_name}} solely with respect to shipments of {{party_name}} shipped prior to the effective date of expiration or termination. Article 19 Miscellaneous 19.1 Assignment; Inurement This {{party_name}} shall be binding upon and shall inure to the benefit of the Parties hereto and their successors and permitted assigns. {{party_name}} shall not assign this {{party_name}}, in whole or in part, to any person without the prior written consent of {{party_name}}, except to a Third {{party_name}} which acquires all, or substantially all, of {{party_name}}’s business or assets, whether through merger or otherwise. {{party_name}} shall be entitled to assign this {{party_name}}, in whole or in part, to any person without the consent of {{party_name}}, provided that (i) such person acquires all, or substantially all, of {{party_name}}’s business or assets with respect to the {{party_name}}, whether through merger or otherwise; (ii) such person is an {{party_name}} of {{party_name}} or a {{party_name}} Licensee; or (iii) {{party_name}} remains liable for any payments {{party_name}} is or will be entitled to under this {{party_name}}. {{party_name}} shall not assign this {{party_name}}, in whole or in part, to any other person without the prior written consent of {{party_name}}, not to be unreasonably withheld, conditioned or delayed. {{effective_date}} {{party_name}} During the {{party_name}}, {{party_name}} will promptly notify {{party_name}} in writing if at any time a {{party_name}} shall occur as to {{party_name}}, such notification to be given no later than fifteen ({{effective_date}} following such {{party_name}}. [* * *] 19.3 Counterparts This {{party_name}} may be executed in any number of counterparts each of which shall be deemed to be an original and all of which taken together shall be deemed to constitute one and the same instrument. 19.4 Dispute Resolution Any controversy or claim arising out of or relating to this {{party_name}}, or the breach thereof, shall be referred first to senior management of the Parties for amicable resolution. In the event that amicable resolution has not been achieved within [* * *], then either {{party_name}} may seek resolution through CONFIDENTIAL Page 41 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. confidential arbitration in accordance with {{party_name}}. The arbitration hearing shall be held as soon as practicable following submission to arbitration. The arbitration hearing shall be held in Delaware. The Parties shall request that the arbitration panel render a formal, binding non-appealable resolution and award on each issue as expeditiously as possible. In any arbitration, the prevailing {{party_name}} shall be entitled to reimbursement of its reasonable attorneys’ fees and the Parties shall use all reasonable efforts to keep arbitration costs to a minimum. Judgment upon the award may be entered by any court having jurisdiction thereof or having jurisdiction over the relevant {{party_name}} or its assets. 19.5 Force Majeure Any delay or inability to perform any of the duties or obligations of either {{party_name}} caused by an event outside the affected {{party_name}}’s reasonable control shall not be considered a breach of this {{party_name}}, and unless provided to the contrary herein, the time required for performance shall be extended for a period equal to the period of such delay. Such events shall include, without limitation: acts of God; any governmental act or regulation; insurrections; riots or civil disturbance; acts of war; embargoes; labor disputes at facilities of Material suppliers, including strikes, lockouts, job actions, or boycotts; fires; explosions; terrorist attacks; floods; or other unforeseeable causes beyond the reasonable control and without the fault or negligence of the {{party_name}} so affected. In order to take the benefit of this section, the {{party_name}} so affected shall give prompt notice [* * *] to the other {{party_name}} of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. If performance is affected for a cumulative period of more than [* * *], the non-affected {{party_name}} may terminate this {{party_name}} immediately by notice in writing to the affected {{party_name}}. 19.6 Performance Each {{party_name}} agrees to perform its obligations under this {{party_name}}, including under any {{party_name}}, in a timely manner. {{party_name}} shall allocate adequate resources to execute its obligations under this {{party_name}}, including under each {{party_name}}. {{party_name}} represents and warrants that all {{party_name}} shall be performed by qualified personnel in accordance with the highest industry standards. 19.7 Further Assurances The Parties shall both execute and deliver such further instruments and do such further acts as may be required to implement the intent of this {{party_name}}. 19.8 Independent Contractors {{party_name}} and {{party_name}} shall be independent contractors and shall not be deemed to be partners, joint venturers or each other’s agents under this {{party_name}}, and neither {{party_name}} shall have the right to act on behalf of the other except as is expressly set forth in this {{party_name}}. CONFIDENTIAL Page 42 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. 19.9 Injunctions Each {{party_name}} agrees that the other {{party_name}} may be irreparably damaged if any provision of this {{party_name}} is not performed in accordance with its terms. Accordingly, notwithstanding Section 19.3, each {{party_name}} will be entitled to apply for an injunction or injunctions to prevent breaches of any of the provisions of this {{party_name}} by the other {{party_name}}, without showing or proving any actual or threatened damage, notwithstanding any rule of law or equity to the contrary, and may specifically enforce such provisions by an action instituted in a court having jurisdiction. These specific remedies are in addition to any other remedy to which the Parties may be entitled at law or in equity. 19.10 Notices Unless otherwise provided herein, any notice required or permitted to be given hereunder or any proposal for any modification of this {{party_name}} (hereinafter collectively referred to as the “{{party_name}}”) shall be faxed, mailed by overnight mail, certified mail postage prepaid, or delivered by hand to the {{party_name}} to whom such {{party_name}} is required or permitted to be given hereunder at the addresses set out below. If delivered by hand, any such {{party_name}} shall be deemed to have been given when received by the {{party_name}} to whom such {{party_name}} is given and if faxed, any such {{party_name}} shall be deemed to have been given on {{effective_date}} following facsimile transmission, as evidenced by written and dated receipt of the receiving {{party_name}}. If to {{party_name}}: CARBOGEN AMCIS {{party_name}} Hauptstrasse 159-173 CH 4416 {{party_name}}: CEO Telephone: + 41 61 935 5353 Facsimile: + 41 61 935 5300 If to {{party_name}}: {{party_name}}, Inc. 75 Park Plaza, 4th {{party_name}}, {{party_name}} General Counsel Phone: +1 617 807 6600 Facsimile: +1 617 275 0039 CONFIDENTIAL Page 43 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Either {{party_name}} may change the address to which any {{party_name}} to it is to be addressed by notification to the other {{party_name}} as provided herein. 19.11 Entire {{party_name}} This {{party_name}}, the Quality {{party_name}} and all {{party_name}} attached hereto (as the same may be amended from time to time by the written agreement of the Parties) constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all other documents, agreements, verbal consents, arrangements and understandings between the Parties with respect to the subject matter hereof. This {{party_name}} shall not be amended orally, but only by an agreement in writing, signed by both Parties that states that it is an amendment to this {{party_name}}. 19.12 Severability If any term or provision of this {{party_name}} shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this {{party_name}} shall be interpreted and construed as if such term or provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never been contained herein. 19.13 Waiver No waiver or modification of any of the terms of this {{party_name}} shall be valid unless in writing and signed by an authorized representative of the Parties hereto. Failure by either {{party_name}} to enforce any rights under this {{party_name}} shall not be construed as a waiver of such rights, nor shall a waiver by either {{party_name}} in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances. [Signature page follows.] CONFIDENTIAL Page 44 of 49 Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. IN WITNESS WHEREOF, each of the Parties hereto has caused this {{party_name}} to be executed by its duly authorized officer as of the dates set forth below. {{party_name}} by its authorized signatory: /s/ {{party_name}}: {{party_name}}. Vice President {{party_name}}: {{effective_date}} CARBOGEN AMCIS {{party_name}} by its authorized signatory: /s/ Silke Erbeck Name: Silke Erbeck Title: Senior Head of Commercial {{party_name}}s {{party_name}}: 10.Jan.2017 /s/ Dr. {{party_name}} {{party_name}} VP Operations CARBOGEN AMCIS {{party_name}} 10.Jan.2017 [Signature page to Outsourcing {{party_name}}] Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Exhibit A – Description of {{party_name}} [* * *] Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Exhibit B – {{party_name}} [* * *] Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. Exhibit C – Fee Schedule [* * *] Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SE{{party_name}}ATELY WITH {{party_name}}. WHERE TWO P{{party_name}}ES OF MATERIAL HAVE BEEN OMITTED, THE REDACTED MATERIAL IS MARKED WITH [†]. Exhibit D – {{party_name}} and Certificate of Compliance [†] Source: {{party_name}}ATEK PHARMACEUTICALS, INC., {{party_name}}, 5/5/2017

Exhibit 10.28 Execution Version OUTSOURCING {{party_name}}REEMENT This OUTSOURCING {{party_name}}REEMENT (this “{{party_name}}”) is made and entered into as of {{effective_date}}, by and among {{party_name}}, a Connecticut corporation with its principal place of business at 15 Secor Road, Brookfield, Connecticut, U.S.A (“{{party_name}}”), {{party_name}}, a Japanese corporation with its principal place of business at 1-1, {{party_name}}, {{party_name}}, Tokyo, Japan (“{{party_name}}”), {{party_name}} {{party_name}} Photomask Corporation, a company limited by shares organized and formed under the {{party_name}} Act of the Republic of China with its principal place of business at {{amount}}, {{party_name}}, Science Park, Hsinchu, Taiwan, ROC (“PDMC”), and {{party_name}}, a limited liability company organized and formed under the People’s Republic of China with its principal place of business at R203-95, South Building of Torch Square, No. 56-58 Torch Road, Gaoxin District, Xiamen, Fujian Province, Peoples Republic of China (the “{{party_name}}”). Each of {{party_name}} and {{party_name}} is hereinafter referred to as a “Shareholder” and collectively as the “Shareholders”, each of the Shareholders and PDMC is hereinafter referred to as a “{{party_name}}” and collectively as the “{{party_name}}s”, and each of the {{party_name}}s and the {{party_name}} is hereinafter referred to as a “{{party_name}}” and collectively as the “Parties.” ARTICLE 1. BACKGROUND {{party_name}} and {{party_name}} wish to participate in a joint venture, either directly or indirectly through their respective {{party_name}}, as equity interest owners in the {{party_name}}, and to carry on the Business through the {{party_name}}. The Parties are engaged, among other things, in the design, development, fabrication and sale of advanced photomasks. {{party_name}} and {{party_name}}, directly or indirectly, are the shareholders of and own PDMC, a joint venture of {{party_name}} and {{party_name}} in Taiwan. In connection with the formation of the {{party_name}}, {{party_name}} and {{party_name}} have entered into “Joint Venture Operating {{party_name}}” (the “China JV Operating {{party_name}}”) dated as of {{effective_date}}. In connection with the China JV Operating {{party_name}} and in order to support the business objective of the {{party_name}}, including but not limited in order to (i) [***]the {{party_name}} desires to outsource or [***]of the {{party_name}} pursuant to the terms and conditions set forth herein. The Parties hereby agree and confirm the exclusive distribution mechanism set forth in Section 10.1 hereof. All terms and conditions for [***]will be governed by this {{party_name}}. Any and all [***]set forth in Section 5.15 of the China JV Operating {{party_name}}. 1.1 Defined {{party_name}}s Unless otherwise defined in this {{party_name}} and Schedule 1 hereof, terms defined in the China JV Operating {{party_name}} shall have the same meanings when used in this {{party_name}}. Source: {{party_name}}, 10-Q/A, 12/19/2017 1.2 Incorporation by Reference Section 12 (Miscellaneous) of the China JV Operating {{party_name}} shall be incorporated by reference into and form an integral part of this {{party_name}}, mutatis mutandis. ARTICLE 2. PURCHASE ORDERS 2.1 Outsource and Issuance of {{party_name}}s Subject to the terms and conditions mentioned hereunder, the Parties agree to the outsource model based on [***]as follows, and the Parties also agree that they may add additional {{party_name}}s to this {{party_name}} through additional {{party_name}}s [***] For the avoidance of doubt, the outsource model is purely made based on the [***] Moreover, it is acknowledged by the Parties that[***] Therefore, subject to the prior notification to, and the instruction and the express approval of the customers, the {{party_name}} could reasonably decide or change the outsource model at its own discretion in accordance with the China JV Operating {{party_name}}. In any case, none of the Parties shall unreasonably [***] of the {{party_name}}s to take advantage of the outsource relationship or [***] A. Outsource Transition Period During the Outsource Transition Period, as for the {{party_name}}s received by the {{party_name}} from: (a) [***] (b) [***] (c) [***] (d) [***]and (e) [***] {{party_name}} (a) During {{party_name}}, the following rules for outsourcing the {{party_name}}s to the {{party_name}}s ({{party_name}}”) will apply: {{effective_date}}: [***] {{effective_date}}: [***] {{effective_date}}: [***] {{effective_date}} and thereafter: [***] For the sake of clarity and by way of example, as for the above calculation; X: [***] Y: [***] Z: [***] 2 Source: {{party_name}}, 10-Q/A, 12/19/2017 (b) If PDMC and the {{party_name}} [***] (i) if [***]or (ii) if [***]. C. General (a) The {{party_name}}s for the [***][***]in accordance with the . (b) PDMC and the {{party_name}} will make best efforts to be [***]The terms and conditions of such [***] (c) For the avoidance of doubt, the Parties agree and confirm that, during the Outsource Transition Period and aside from {{party_name}} in [***]. (d) The Parties acknowledge and agree that [***] 2.2 {{party_name}}s The {{party_name}} will make good faith efforts to accept all [***]from the {{party_name}} that comply with this Agreement including adhering to all relevant specifications of the Product as set forth in the [***]entered into between the {{party_name}} and the {{party_name}} (including the [***] (as defined below)). The {{party_name}} shall notify the {{party_name}} of acceptance or rejection of a [***]within [***]hours of receipt of a [***]. Failure of the {{party_name}} to accept or reject a [***]within [***]hours shall constitute acceptance of such [***]. The lead time for the Products will be as set forth in the applicable [***]. Each [***]shall include the following: (a) the {{party_name}}’s [***]number; (b) identification of the quantity and type of the Product ordered by the {{party_name}}; (c) the price of each Product ordered per {{party_name}} attached hereto; (d) the requested delivery date (subject to the applicable Product Lead Time); (e) any shipping instructions, including preferred carrier and shipping destination; and (f) the specifications for the Product. Notwithstanding anything contained in this Agreement and {{party_name}} to the contrary, and for the sake of clarity, [***]. 2.3 {{party_name}} Terms All [***]agreed to between the {{party_name}} and a {{party_name}} shall be governed by this Agreement unless otherwise agreed by the {{party_name}} and the [***]which receives such [***]in writing; the Parties agree that the [***]submitted by the {{party_name}} to any of the [***] will mirror the terms and conditions of the [***]with respect to specification for the Product and the end customer’s requirement submitted to the {{party_name}} by the {{party_name}}’s [***]. Those terms and conditions of the [***]may be discussed and agreed between the {{party_name}} and any of the {{party_name}} prior to issuance of such [***]to any of the [***]. 2.4 Rescheduling and Cancellation The {{party_name}} may not [***]any portion of an accepted [***]unless the {{party_name}} fails to fulfill any material term of such accepted [***]. The {{party_name}} shall at all times use prudent material planning practices, including by way of example, [***]. The {{party_name}} [***]will be provided on a [***] basis covering a rolling [***]period. The {{party_name}} will provide the {{party_name}} with such [***]which will be updated [***] and [***]which will be updated [***] and will be used for planning purposes only. If a {{party_name}}’s ability to supply any Product is constrained for any reason, such {{party_name}} shall immediately notify the {{party_name}} of such supply constraint for the purpose of resolving the same. 3 Source: {{party_name}}, 10-Q/A, 12/19/2017 2.5 End of Life Each of the {{party_name}} may terminate its obligations to supply a particular Product under this Agreement by giving written notice of the end of life of such Product to the {{party_name}} at least [***]before the effective date of such termination (a “Product EOL Notice”), provided that (a) the relevant {{party_name}} shall supply, and the {{party_name}} shall purchase, such Product ordered pursuant to this Agreement until the effective date of such termination and including any accepted {{party_name}}s outstanding on the effective date of termination, and (b) the relevant {{party_name}} is [***]to its other [***] with respect to such Product. When the {{party_name}} becomes aware that any of its customers will finish purchasing any type of the Products, the {{party_name}} shall promptly notify the {{party_name}}(s) thereof. Notwithstanding the above, if the {{party_name}} has a long term supply agreement with a customer and the {{party_name}} (i) has confirmed in writing its intention to [***] hereunder and (ii) are actually providing Product in support of such supply agreement, neither {{party_name}} can, to the extent of its confirmation, to supply the {{party_name}} until such s[***]; provided however that, if a Shareholder terminates the [***], such Shareholder can immediately terminate [***]. 2.6 Certain Claims Notwithstanding any other provisions in this Agreement, either {{party_name}} may [***]after {{party_name}}’ receipt of a written [***] that is deemed credible by written opinion of the relevant {{party_name}}’s outside counsel, provided that the relevant {{party_name}} also [***] with respect to such Product; provided further that (i) relevant {{party_name}} shall give the {{party_name}} at [***]calendar {{effective_date}} prior written notice of its intent to discontinue [***], and (ii) at the {{party_name}}’s request, if the {{party_name}} will using the [***], {{party_name}} will provide the {{party_name}} with all reasonable information and assistance necessary, [***]to the relevant [***]in accordance with the terms and conditions to be agreed by the relevant {{party_name}} and the {{party_name}}, to enable the {{party_name}} to manufacture or have the [***]. Any such granted [***]shall [***] and provided information shall be destroyed or returned in the event the relevant {{party_name}} resumes[***]. The {{party_name}} shall defend, indemnify and hold harmless the relevant {{party_name}} from and against any claims, expenses and costs (including but not limited to attorney and other professional fees and expenses), settlement of third party claims (if negotiated and approved by the {{party_name}}), damages and liability arising from or related to [***]or the violation of the [***] of any [***]solely with respect to the {{party_name}}’s manufacture, use, sale, offering for sale, importation or distribution of any [***]during the [***]calendar {{effective_date}} period specified in this Section 2.6 or manufactured by or on behalf of the {{party_name}} under the license granted in this Section 2.6. 2.7 Priority for New Products [***] for the {{party_name}} will be reviewed and discussed by {{party_name}}. The {{party_name}} role will be as defined in Section 5.15 of {{party_name}}. ARTICLE 3. PURCHASE ORDER ALLOCATION Notwithstanding any other provisions in this Agreement, the Parties agree that, [***]hereunder by the {{party_name}} to any of the {{party_name}} shall be at [***] pursuant to the [***]of the {{party_name}} taking into account the [***]of the {{party_name}}’s [***]and the [***] for the [***]; provided however that the {{party_name}} will attempt to allocate the [***] with each {{party_name}} pursuant to the [***]set forth in Section 2.1 above. The Parties will review the [***] of orders between {{party_name}} on a [***]. If at the end of each [***]the [***]to one of the {{party_name}} is not consistent with the [***]set forth in Section 2.1 above, the {{party_name}} will attempt to [***]to the {{party_name}} with [***]for the [***]until such {{party_name}} has received [***]set forth in Section 2.1 above. Notwithstanding the above, each of the Parties agrees and acknowledges that if a {{party_name}} cannot provide Product to the {{party_name}} because of [***]of the {{party_name}}, then the {{party_name}} will be [***] to seek the Product from the other {{party_name}} without [***]of Product orders between the {{party_name}}. 4 Source: {{party_name}}, 10-Q/A, 12/19/2017 ARTICLE 4. PRODUCT PRICES AND PAYMENT 4.1 Prices The purchase price for the Product shall be as set forth in {{party_name}}. 4.2 Invoices; Payments The {{party_name}} shall issue invoices to the {{party_name}} for any amounts payable to the {{party_name}} pursuant to this Agreement upon shipment of the applicable Products to the {{party_name}}. Payments for Products delivered in accordance with the {{party_name}}s, and any other to be made by the {{party_name}} to {{party_name}} hereunder, shall be made in the {{party_name}} Currency within [***]from the shipment of the applicable Products delivered. 4.3 Taxes All amounts payable for Product sold by the {{party_name}} to the {{party_name}} hereunder are exclusive of any taxes. The {{party_name}} shall be responsible for and shall pay any applicable sales, use, excise or similar taxes, including value added taxes and customs duties due on the importation of the Products and arising from purchases made by the {{party_name}} under this Agreement, excluding any taxes based on the {{party_name}}’ income and any applicable withholding taxes. All such taxes shall be determined based upon the final shipment designation of the items identified on the invoice. ARTICLE 5. DELIVERY 5.1 Risk of Loss and Title Delivery of all Products shall be made pursuant to the Delivery Term. Risk of loss for the Products and title to the Products shall pass to the {{party_name}} in accordance with the Delivery Term. 5.2 Delivery {{party_name}} shall deliver the Product to the {{party_name}} in accordance with the Delivery Term, shipping instructions in the {{party_name}} issued by the {{party_name}} with regard to the requested delivery date (subject to {{party_name}}), ship-to address, and carrier. If the {{party_name}} does not provide shipping instructions, the {{party_name}} will select the carrier on a commercially reasonable basis. {{party_name}} shall be responsible for paying freight, handling, shipping and/or insurance charges to the delivery point in accordance with the Delivery Term. 5 Source: {{party_name}}, 10-Q/A, 12/19/2017 ARTICLE 6. LIMITED WARRANTIES 6.1 {{party_name}} Limited Warranty Each of the {{party_name}} warrants that the Products shall comply with the specifications and documentation agreed by the relevant {{party_name}} and the {{party_name}} in writing that is applicable to such Products for the Warranty Period. This warranty does not apply to any Product failures resulting from misuse, storage in or exposure to environmental conditions inconsistent with those specified in the applicable specifications or documentation, modification of the Product by anyone other than the relevant {{party_name}}. If a Product fails to comply with the foregoing warranty, the relevant {{party_name}} shall, at its option, either [***]such Product, or, in the event the foregoing options are not commercially practicable, [***]to the {{party_name}} any amounts paid for the applicable Product. Without limiting the remedies specified in Article 8 and Section 9.2, this Section 6.1 states the exclusive remedy of the {{party_name}} for failure of a Product to conform to the warranty provisions set forth in this Section 6.1. 6.2 Disclaimer EXCEPT AS {{party_name}} FORTH IN THIS ARTICLE 6, THE PARTIES MAKE NO WARRANTIES OR REPRESENTATIONS TO THE OTHER PARTIES AND EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, {{party_name}} OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE. ARTICLE 7. TERM AND TERMINATION 7.1 Term This Agreement shall become effective as of {{party_name}} and shall continue to be in full force and effect for so long as {{party_name}} and {{party_name}}, or any of their {{party_name}}, each remains a Shareholder of the {{party_name}}. 7.2 Termination for Cause A {{party_name}} shall have the right to terminate its obligations under this Agreement if the other {{party_name}} materially breaches this Agreement and fails to cure such breach within thirty (30) {{effective_date}} after its receipt of written notice of the breach specifying such default. 7.3 Survival Article 6 (for the duration of the applicable warranty period), Article 7, Article 8 and Article 9 shall survive any termination or expiration of this Agreement. ARTICLE 8. INDEMNIFICATION 8.1 Indemnification by the {{party_name}} Each of the {{party_name}} shall, with respect to Products supplied by such {{party_name}}, defend, indemnify and hold harmless the {{party_name}} from and against any third party claims, expenses and costs (including but not limited to attorney and other professional fees and expenses), settlement (if negotiated and approved by the relevant {{party_name}}), damages and liability to the extent arising from a claim (a) alleging that a Product infringes or misappropriates any {{party_name}}, or (b) arising under products liability theory from a manufacturing defect, and shall pay any judgments finally awarded by a court or any amounts contained in a settlement agreed to by the relevant {{party_name}} arising from such claims. The foregoing indemnity does not cover claims that solely arise from (i) the modification of the Product by any party other than the relevant {{party_name}}, (ii) the combination or use of the Product with other products, processes, methods, materials or devices except as approved by the relevant {{party_name}}, or (iii) the fault of the {{party_name}}. 6 Source: {{party_name}}, 10-Q/A, 12/19/2017 8.2 Indemnification by the {{party_name}} Other than claims for which the {{party_name}} are obligated to indemnify the {{party_name}} under Section 8.1, the {{party_name}} shall defend, indemnify and hold harmless the {{party_name}} from and against any third party claims, expenses and costs (including but not limited to attorney and other professional fees and expenses), settlement (if negotiated and approved by the {{party_name}}), damages and liability to the extent arising from a claim (a) alleging that a Product supplied by such {{party_name}} infringes or misappropriates any {{party_name}}, or (b) arising under products liability theory from a manufacturing defect, and shall pay any judgments finally awarded by a court or any amounts contained in a settlement agreed to by the {{party_name}} arising from such claims. The foregoing indemnity does not cover claims that solely arise from (i) the modification of the Product by any party other than the {{party_name}}, or (ii) the combination or use of the Product with other products, processes, methods, materials or devices except as approved by the {{party_name}}. 8.3 Procedure The {{party_name}} seeking indemnification hereunder (the “Indemnified {{party_name}}”) agrees to promptly inform the other {{party_name}} (the “Indemnifying {{party_name}}”) in writing of such claim and furnish a copy of each communication, notice or other action relating to the claim and the alleged infringement. The Indemnified {{party_name}} shall permit the Indemnifying {{party_name}} to have sole control over the defense and negotiations for a settlement or compromise, provided that the Indemnifying {{party_name}} may not settle or compromise a claim in a manner that imposes or purports to impose any liability or obligations on the Indemnified {{party_name}} without obtaining the Indemnified {{party_name}}’s prior written consent. The Indemnified {{party_name}} agrees to give all reasonable authority, information and assistance necessary to defend or settle such suit or proceeding at the Indemnifying {{party_name}}’s reasonable request and at the Indemnifying {{party_name}}’s expense. ARTICLE 9. {{party_name}} AND REMEDY 9.1 {{party_name}} FOR {{party_name}} ARISING FROM BREACHES OF A PARTY’S {{party_name}} IN THE NON-DISCLOSURE CLAUSE IN SECTION 12.17 OF THE CHINA JV OPERATING {{party_name}}MENT, BREACHES OF LICENSE GRANTS CONTAINED HEREIN, AND EXCEPT FOR AMOUNTS PAYABLE TO THIRD PARTIES TO FULFILL INDEMNITY OBLIGATIONS DESCRIBED IN ARTICLE 8, (A) IN NO EVENT SHALL ANY PARTY HAVE ANY {{party_name}} TO THE OTHERS, OR TO ANY PARTY CLAIMING THROUGH OR UNDER THE OTHER, FOR ANY LOST PROFITS, ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND IN ANY WAY ARISING OUT OF OR RELATED TO THIS {{party_name}}MENT, HOWEVER CAUSED AND UNDER ANY THEORY OF {{party_name}}, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE {{party_name}} OF SUCH DAMAGES; AND (B) IN NO EVENT SHALL A PARTY’S CUMULATIVE {{party_name}} ARISING OUT OF THIS {{party_name}}MENT EXCEED THE AMOUNTS ACTUALLY PAID, PAYABLE, {{party_name}} OR RECEIVABLE BY SUCH PARTY FOR THE PRODUCTS CONCERNED THEREWITH HEREUNDER PURSUANT TO THIS {{party_name}}MENT DURING THE {{party_name}} (12) MONTHS PRIOR TO THE OCCURRENCE OF {{party_name}}. THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY REMEDY. THE PARTIES ACKNOWLEDGE AND {{party_name}} THAT THIS ARTICLE 9 IS AN ESSENTIAL ELEMENT OF THE BARGAIN AND ABSENT THIS ARTICLE 9 THE ECONOMIC AND OTHER TERMS OF THIS {{party_name}}MENT WOULD BE SUBSTANTIALLY DIFFERENT. 7 Source: {{party_name}}, 10-Q/A, 12/19/2017 9.2 Remedies Notwithstanding anything stated to the contrary in this Agreement, the Parties acknowledge that any breach of Section 2.5 [***]of this Agreement and/or the non-disclosure clause in Section 12.17 of {{party_name}} by a {{party_name}} would cause irreparable harm to the other Parties, and that the damages arising from any such breach would be difficult or impossible to ascertain. As such, the Parties agree that a {{party_name}} shall be entitled to injunctive relief and other equitable remedies in the event of any breach or threatened breach of Section 2.5 of this Agreement and/or the non-disclosure clause in Section 12.17 of {{party_name}}. Such injunctive or other equitable relief shall be in addition to, and not in lieu of, any other remedies that may be available to that {{party_name}}. The Parties shall be entitled reasonable attorney fees and costs of enforcement of this Agreement. ARTICLE 10. OTHER ARRANGEMENT [***][***]. (Signature Page Follows) 8 Source: {{party_name}}, 10-Q/A, 12/19/2017 Execution Version IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of {{effective_date}} above written. {{party_name}} By: Name: [***] Title: [***] {{party_name}}, {{party_name}}. By: Name: [***] Title: [***] {{party_name}} {{party_name}} Mask Corporation . By: Name: [***] Title: [***] {{party_name}} {{party_name}} Mask Corporation Xiamen By: Name: [***] Title: [***] Outsourcing Agreement Signature Page Source: {{party_name}}, 10-Q/A, 12/19/2017 Schedule 1 Definitions Capitalized words and phrases used and not otherwise defined elsewhere in this Agreement shall have the following meanings: 1. “{{party_name}}” of a Person means any other Person which, directly or indirectly, controls, is controlled by, or is under common control with, such Person. The term “control” (including, with correlative meaning, the terms “controlled by” and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise. A Person shall be deemed an {{party_name}} of another Person only so long as such control relationship exists. 2. “{{party_name}} Currency” means (i) for payments in relation to {{party_name}}, {{party_name}}, (ii) for payments in relation to {{party_name}}, {{party_name}}, and (iii) for payments in relation to PDMC, {{party_name}}. 3. “Delivery Term” means DDP (Incoterms {{effective_date}}) at delivery point in China. The Delivery Term may be otherwise determined by the {{party_name}} and the {{party_name}} in the {{party_name}} where delivery point is other place than China. 4. [***]. 5. “{{party_name}}” means all rights in and to (a) U.S. and foreign patents and patent applications, including all divisions, substitutions, continuations, continuations-in-part, and any reissues, re-examinations and extensions thereof, (b) copyrights and other rights in works of authorship, (c) unpatented inventions, trade secrets, data, processes, or materials, (d) mask work rights, and (e) other intellectual property or proprietary rights of any kind now known or hereafter recognized in any jurisdiction, but excluding trademarks, service marks, trade names, trade dress, domain names, logos and similar rights, and the goodwill associated therewith. 6. [***]. 7. [***]. 8. [***]. 9. [***]. 10. [***]. 11. “Product” means photolithographic integrated circuit photomasks for [***] and related services. 12. “{{party_name}}” means any of the following (a) a written purchase order issued to the {{party_name}} by third party buyers for the purchase of certain Products; (b) a written purchase order issued by the {{party_name}} to a {{party_name}} for a quantity of the Product. 13. “Warranty Period” means a period of [***]from the relevant {{party_name}}’s shipment of the Product. *** Confidential treatment has been requested by {{party_name}}, Inc. for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to {{party_name}}. Source: {{party_name}}, 10-Q/A, 12/19/2017 {{party_name}} Product Prices The prices for each Product outsourced to the {{party_name}} shall be [***]. *** Confidential treatment has been requested by {{party_name}}, Inc. for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to {{party_name}}. Source: {{party_name}}, 10-Q/A, 12/19/2017

